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AN ASSESSMENT OF HPV VACCINATION BY GEORGIA PHYSICIANS: 
KNOWLEDGE, BARRIERS, SUPPORTS, PRACTICES, AND ADHERENCE TO 
ACIP GUIDELINES AND RECOMMENDATIONS 
 
 
by 
 
ELIZABETH DIXON  
 
 
(Under the Direction of John Luque) 
ABSTRACT 
The purpose of this study was to examine Georgia physicians’ administration of the 
quadrivalent human papillomavirus (HPV) vaccine to 11-12 year old females according 
to the Advisory Council Immunization Practices (ACIP) guidelines, their intention to 
recommend HPV vaccine to 11-12 year old males, and their perceived knowledge and 
barriers associated with HPV vaccination.  A distinction between urban and rural was 
examined to determine if there were differences in HPV vaccination recommendation.  A 
stratified sample was created from the Georgia Vaccine For Children (VFC) provider list.  
The final sampling frame included 264 (n = 264) providers.  Of these, 218 physicians 
were contacted yielding a response rate of 82.6%.  Forty-two were located in rural 
counties and 176 were located in urban counties.  Examination of perceived barriers, 
perceived knowledge and administration practices revealed no differences between urban 
and rural physicians.  Approximately one in ten Georgia physicians (12%) who 
responded reported they always vaccinate 11-12 year old females.  The number increased 
to one in five (22.9%) who always vaccinate females age 13-17 years, suggesting parents 
or physicians may be delaying vaccination until females are older than 12 years.  
  
Approximately one quarter (23.7%) recommend the vaccine to their male patients.  More 
than half (59.4%) reported insufficient insurance coverage for the vaccine as a barrier to 
vaccinating males and females.  In multivariate logistic regression models, variables 
independently associated with not recommending to 11-12 year old females included: 
female gender of the physician (OR, 3.07; 95% CI, 1.02-9.29) and parental barriers (OR 
1.15; CI, 1.04-1.29).  There were no associated findings with not recommending male 
vaccination.  Findings from this study may serve as a helpful resource for further 
assessment of HPV vaccination in Georgia and targeting educational and policy 
interventions. 
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CHAPTER 1 
BACKGROUND SIGNIFICANCE AND LITERATURE REVIEW 
Introduction 
The human papillomavirus (HPV) is the most common sexually transmitted virus in the 
United States and it is estimated that 70% of sexually active men and women acquire an 
infection at some point during their lifetime (CDC, 2010). In total numbers, approximately 20 
million people in the United States are currently infected with 6.2 million new infections 
annually (Dunne & Markowitz, 2006). Using census figures (Census Bureau 2010) for Georgia 
(n= 9,829,211), approximately 633,000 people in are Georgia currently infected with genital 
HPV, and approximately 20,000 people in Georgia will acquire a new genital HPV infection 
each year.  
In the majority of people, HPV infections are not serious.  Most infections are 
asymptomatic, transient, and resolve without medical intervention.  While an HPV infection is 
necessary for the development of precursor lesions and cervical cancer, it is not always sufficient 
to cause cervical abnormalities (CDC, 2010).  However, continuous infection of one or more 
high-risk HPV types, particularly subtypes 16 and 18, can result in precursor lesions and cervical 
cancer (Muñoz et al., 2003).  Approximately 11,000 cases of cervical cancer occur in the United 
States annually.  Of these 11,000 cases, approximately 36.4% will result in death (NCI, 2010).  
Cervical cancer also causes and economic burden and it is estimated that over $2 billion dollars 
is spent annually on the treatment of cervical cancer in the United States (CDC, 2010).  
Estimates for the incidence and prevalence of genital warts caused by low-risk HPV types 6 
and 11 are inexact.  However, it is estimated that 5.6% of sexually active adults age 18 to 59 
years living in the United States report ever being diagnosed with genital warts (Dinh, Dunne, & 
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Markowitz, 2008).  According to the Centers for Disease Control and Prevention (CDC), there 
are approximately one million new cases of genital warts each year in the United States (CDC, 
2010). 
 Although genital warts are commonly perceived as a non-serious condition, treatment is 
often lengthy with 25% of cases reoccurring within three months (Mandell, Bennett, & Dolin, 
2009).  Men and women who participated in a study by Mortensen (2010) considered quality of 
life to be significantly lowered because of genital warts, and participants expressed negative 
psychological and social effects.  They also believed genital warts were associated with adverse 
consequences of daily life and affect the ability to develop new relationships.  Women who took 
part in a study by McCaffery et al. (2006) described feeling stigmatized, anxious and stressed.  
They were concerned about new relationships and worried about disclosing their condition to 
others.  This was also true regarding the psychological burden of the HPV infection and the 
woman’s relationship status and history, their social and cultural norms and practices around sex 
and relationships, as well as their understanding of key features of HPV (McCaffery, Waller, 
Nazroo, & Wardle, 2006).   
The burden of HPV infection and cervical cancer can be eliminated now that a vaccine 
targeting the HPV virus has been developed.  On June 8th, 2006, the U.S. Food and Drug 
Administration (FDA) approved Gardasil® by Merck Pharmaceuticals as the first quadrivalent 
HPV vaccine to protect women from HPV infection of subtypes 6, 11, 16, and 18 (Markowitz et 
al., 2007).  Less than one year later, in 2007, the Advisory Council on Immunization Practices 
(ACIP) of the CDC recommended all girls aged 11 and 12 years be vaccinated against HPV, 
with the indication that girls as young as 9 years of age, and older females between the ages of 
13 and 26 may receive the vaccine at their providers’ discretion (Markowitz  et al., 2007). 
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In order for the HPV vaccine to be most effective, it must be administered prior to onset of 
sexual activity and the exposure to the HPV virus, which requires administering to pre-
adolescents and young adolescents (Markowitz et al., 2007).  Dempsey, Koutsky, and Golden 
(2007) indicate HPV is “nearly ubiquitous among sexually active individuals….” (p.506) and 
further note “… individuals do not need to engage in high-risk sexual behavior to become 
infected.…” (p. 506) thus indicating the vaccine must be administered early rather than later if it 
is to be effective.   
In another study involving 60 adolescent women, 27% of a group of females were infected 
with HPV.  This increased to 45% for females aged 14 to 24, leading researchers to conclude that 
the “cumulative prevalence of HPV infection in sexually active adolescent women is extremely 
high” (Brown et al., 2005).  Research by Hopenhayn, Christian, Christian, and Schoenberg 
(2007), report one-third of Kentucky ninth graders admit to having sexual intercourse and two-
thirds report doing so by the time they are seniors in high school.  Charo (2007) noted youth 
dropout rates from school begin to increase after age 13 and youth who leave school are more 
likely to engage in sexual activity earlier. 
As we learn more about the early onset of sexual activity of adolescents and their increased 
risk for HPV infection, it becomes apparent a vaccine protective of both males and females 
would be beneficial if the virus is to be defeated.  This is further noted as there is a high rate of 
transmission of HPV in female partners of men with pre-existing genital warts, and HPV 
infection in men has been shown to contribute to HPV infection and subsequent cervical disease 
and cancer in women (MMWR, May, 2010).  On October 16, 2009, the FDA approved the same 
quadrivalent HPV vaccine, Gardasil®, for use in boys and men 9 through 26 years of age for the 
prevention of genital warts caused by HPV subtypes 6 and 11.  In addition, this vaccine offers 
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protection to their female partners against subtypes 6 and 11, making it the only HPV vaccine 
approved for use in males (FDA, 2009).   
Presently, there is debate on the cost effectiveness of the HPV vaccine and the potential for 
herd immunity given that it has been recommended to both females and males.  In a presentation 
to the ACIP on October 21, 2009, a CDC Health Economist, Dr. Harrell Chesson, stated factors 
associated with HPV vaccination cost effectiveness include protection against HPV subtypes 6, 
11, 16, and 18, duration of protection, degree of cross protection, and vaccine price (Chesson, 
2009).  According to Chesson’s research, the possible reduction in the fifty million annual 
cervical cytology (Pap) screens to detect cervical disease is an important benefit of HPV 
vaccination (Chesson, 2009).  In a 2011 report to the ACIP, Dr. Chesson noted 12 year old girls 
who received the vaccine had a cost per quality-adjusted life year ranging from $3,000 to 
$45,000 (CDC, 2011). 
 A national study of physicians’ intentions regarding the impact of HPV vaccine on cervical 
cancer screening further indicates a reduced number of future Pap screens for women who have 
had the HPV vaccine (Wong, Berkowitz, Saraiya, Wideroff, & Bernard, 2010).  Internal 
medicine physicians who responded to the survey agreed that vaccination would affect Pap 
screening frequency by reducing the number of Pap screens needed over the lifetime of the 
woman.   
According to the annual report of cancer statistics, cervical cancer caused by the HPV virus 
occurs most often in women aged 30 years and older (Jemal, 2009).  In 2009, 11,270 women in 
the United States were diagnosed with cervical cancer and 4,070 died from the disease (Jemal et 
al., 2009).  Healthy People 2010 created a focus on cervical cancer with Cancer Goal 3-4, 
“Reduce the death rate from cancer of the uterine cervix to a target of 2.0 deaths per 100,000 
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females” (USDHHS, 2000).  The rate of cervical cancer in the United States is 2.5 per 100,000 
and the rate for Georgia is 2.7 per 100,000 (State Cancer Profiles, 2010).  In 2006, the U.S. rate 
was reported to be 2.5.  Counties in Georgia with the highest mortality for cervical cancer 
include Chatham, Fulton, Richmond, Gwinnett, and Cobb Counties (NCI, 2010).  The National 
Cancer Institute’s State Cancer Profile reported that Georgia had an estimated 364 new cases of 
cervical cancer in 2006, resulting in 122 deaths from the disease (State Cancer Profiles, 2010).  
However, despite having this vaccine available, only 38% of female teens in Georgia have been 
vaccinated with at least one of the three doses that are necessary for HPV immunity (MMWR, 
2010). 
Health disparities among certain groups with higher rates of cervical cancer are noted. 
Smith, Christopher and McCormick (2004) and suggest African Americans are currently 1.5 
times more likely to experience an incidence of cervical cancer and two times more likely to 
experience mortality than Caucasian women.  Incidence rates for Hispanic and some Asian 
subpopulations are also reported to be higher than Caucasian rates.  Moreover, women of 
Mexican descent typically receive the least preventative care services within Latina populations 
(Scarinci et al., 2010).  Data also suggest immigrants from Southeast Asia have the lowest levels 
of Pap screens of all racial/ethnic populations in the United States (Jackson et al., 2000).  Finally, 
southern states, including Georgia, have a higher incidence of cervical cancer (Markowitz et al., 
2007).  
While the economic impact of cervical cancer can have ill effects upon the local economy, a 
more insidious economic impact is the cost of testing for cervical cancer by obtaining numerous 
Pap screenings throughout the life span.  The National Health Interview Survey notes that fifty 
million tests for cervical cancer through Pap screens are performed annually in the United States 
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(Hiatt, Klabunde, Breen, Swan, & Ballard-Barbash, 2002).  Women who follow the American 
College of Gynecology guidelines will obtain multiple Pap screens during their lifetime (ACOG 
Practice Bulletin, 2006).  Having immunity against four of the HPV subtypes will not entirely 
protect against all cervical cancers, but this protective factor may decrease the number and need 
for many Pap screens during a women’s lifetime. 
The FDA-approved quadrivalent HPV vaccine Gardasil® targets the HPV strains 
responsible for approximately 70% of cervical cancers and 90% of genital warts making it a very 
effective vaccine if given at the proper stage (Bratten & Laufer, 2008, MMWR, 2010).  Yet, 
despite the availability of this vaccine, it is estimated that 44.3% of eligible girls nationally and 
38% in Georgia have been vaccinated with at least one of the three doses required for HPV 
immunity (MMWR, 2010).  There is a clear need for a better understanding of the benefits of 
this vaccine.  
Purpose of the Study 
The purpose of this study was to examine the prevalence of Georgia physician intention and 
administration of the HPV vaccine to 11-12 year-old girls, as well as the intention to recommend 
the HPV vaccine to 11-12 year old boys.  The study examined the attitudes and beliefs of 
Georgia physicians toward administering the HPV vaccine and assessed perceived knowledge, 
barriers, practices, and adherence to ACIP guidelines and recommendations regarding HPV 
vaccination.  A survey was administered to a random sample of 264 Georgia physicians yielding 
a response rate of 82.6% (n= 218).  Respondents to the survey were asked to describe their 
intention and prevalence of administering the HPV vaccine to their female and male patient 
population.  Respondents were then asked about their knowledge of the HPV vaccine and if they 
administered the vaccine according to ACIP guidelines by offering it to females at 11-12 years of 
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age.  They were also asked if they recommended it according to ACIP guidelines of “permissive 
use” to 11-12 year old males.  Respondents were asked to respond to barriers they perceive to be 
associated with this vaccine.  A distinction between urban and rural was examined to determine 
if there were differences.  The Health Belief Model (Becker, 1974, Champion & Skinner, 2008; 
Glanz, Rimer, & Viswanath, 2008) was use to inform this study of Georgia physicians.  
Significance of the Study 
At present, less than half the eligible girls in Georgia receive the HPV vaccine (MMWR, 
2010).  The body of knowledge obtained through this study, indicating how and to whom 
Georgia physicians are administering the vaccine, will be beneficial in planning future 
immunization actions and interventions. The current study, as designed, provided the first 
comprehensive examination of HPV vaccination of physician practices in Georgia. By 
addressing issues related to physician endorsement and recommendation of this vaccine, the 
study will serve as an important and necessary step toward realizing the public health benefits of 
HPV vaccination.  This study will contribute information to the body of knowledge of HPV 
vaccination in general and in particular, for the state of Georgia. 
The study examined Georgia physician recommendations and prevalence of immunization 
of the HPV vaccine to 11-12 year-old girls and intention to recommend the HPV vaccine to 11-
12 year old boys. The study examined the attitudes and beliefs of Georgia physicians toward 
administering the HPV vaccine and assessed perceived knowledge, barriers, practices, and 
adherence to ACIP guidelines and recommendations regarding HPV vaccination.  
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Literature Review 
Human Papillomavirus  
According to the CDC (2010) there are more than 40 HPV types that can infect the genital 
areas of males and females although subtypes 6, 11, 16 and 18 are the most prevalent.  HPV is 
passed on through genital contact, most often during vaginal and anal sex.  HPV can be passed 
on even when the infected partner has no signs or symptoms.  A person can have HPV even if 
years have passed since he or she had sexual contact with an infected person. Most infected 
persons do not realize they are infected or that they are passing the virus to a sex partner.  It is 
also possible to be infected with more than one type of HPV.   
HPV can cause normal cells to turn abnormal. The infected person cannot see or feel these 
cell changes. In most cases, the body fights off HPV naturally and in 90% of cases, the body’s 
immune system clears HPV naturally within two years (CDC, 2010).  But in cases when the 
body does not fight off HPV, it can cause visible changes in the form of genital warts or cancer. 
Warts can appear within weeks or months after getting HPV.  Cancer often takes years to 
develop after getting HPV.   
Genital warts usually appear as a small bump or groups of bumps in the genital area. They 
can be small or large, raised or flat, or shaped like a cauliflower.  If left untreated, genital warts 
may resolve, remain unchanged, or increase in size or number. They will not turn into cancer.  
Cervical cancer usually does not cause symptoms until it is quite advanced and difficult to treat 
(Rock & Jones, 2008). 
Cervical Cancer 
Cervical cancer is a malignant and excessive growth of abnormal tissue of the cervical area 
that left untreated may be fatal (Young, O’Dowd, & Stewart, 2010).  In 2009, 11,270 women in 
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the United States were diagnosed with cervical cancer and 4,070 died from the disease (Jemal et 
al., 2009).  The HPV infection is a necessary factor in the development of nearly 70% of all 
cases of cervical cancer (Young et al., 2010). The two subtypes of HPV are types 16 and 18, and 
these subtypes are the cause of over 70% of cervical cancer cases and are included in the HPV 
vaccine (CDC, 2008; Markowitz et al., 2007). 
TeLinde’s operative gynecology (2008) notes presentation of cervical cancer may be absent 
until the cancer is in an advanced stage making it difficult for women to seek early treatment. 
Cervical cancer is comprised of five stages to determine the amount of cancer in the body. In the 
initial Stage, or Stage 0, abnormal cells are found in the deepest lining of the cervix.  Stage 0 is called 
carcinoma in situ and is found in the cervix.  Stage 0 is followed by Stage I which includes 
growth of the cancer.  The five year survival rate for Stage I range from 80-99%. Common 
treatments include surgery, chemotherapy and radiation (NCI, 2010).   
In Stage II, cancer has spread beyond the cervix but not into the pelvic wall or to the lower third 
of the vagina.  Five-year survival is 65-69%. Common treatments for Stage II cervical cancer include 
surgery, radiation and chemotherapy (NCI, 2010). 
In Stage III, cancer has spread to the lower third of the vagina and may have spread to the pelvic 
wall.  With advanced cervical cancer, the woman has symptoms of weight loss, a vague feeling 
of fatigue, pelvic pain, back pain, leg pain, a single swollen leg, heavy bleeding from the vagina, 
possible leaking of urine or feces from the vagina, or bone fractures (Rock & Jones III, 2007).  
Five-year survival at this state is 40-43 %. Common treatments include chemotherapy and radiation 
(NCI, 2010).   
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In Stage IV, the cancer has left the pelvis and spread to the bladder, rectum, or other parts of the 
body such as the abdomen, liver, intestinal tract, or lungs.  The five-year survival rate for this stage 
of cancer is 15-20 %.  Types of treatment include chemotherapy and radiation (NCI, 2010).  
Each year the American Cancer Society (ACS) publishes a summary of recommendations 
for early cancer detection and a report on data and trends in cancer screening rates.  The ACS 
reviews current guidelines by the US Preventive Services Task Force and from the American 
College of Obstetricians and Gynecologists (ACOG).  The ACS screening guidelines for cervical 
cancer recommend different surveillance strategies and options based on the woman’s age, 
screening history, other risk factors, and the choice of screening tests (Smith, Cokkinides, 
Brooks, Saslow, & Brawley, 2010).  The ACS guidelines for cervical cancer screening were 
updated in 2009 to include best practices since the changes made in the 2002 update.  The 2009 
ACS guidelines recommend screening for cervical cancers begin at age 21 years.  Until age 30, 
and according to the guidelines, women at average risk receive biannual Pap screening using 
liquid-based cytology.  After age 30 years, women with normal or negative Pap screens may 
choose either to undergo screening every three years using either conventional or liquid-based 
cytology, or undergo screening every three years with the combination of HPV-DNA testing and 
conventional or liquid-based cytology (Smith et al., 2010; Waxman, 2009).  
The current guidelines recommend women who have an intact cervix and who are in good 
health continue screening until age 70 years, and afterward may choose to stop screening if they 
have had no abnormal or positive cytology tests within the 10-year period prior to age 70 years, 
and if there is documentation that the three most recent Pap screens were technically satisfactory 
and interpreted as normal.  However, screening after age 70 years is recommended for women in 
good health who have not been previously screened, women for whom information about 
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previous screening is unavailable, and women for whom there is a low likelihood of past 
screening (Smith et al., 2010; Waxman, 2009). 
The US Public Health Service and Infectious Disease Society of America also have 
recommendations for cervical cancer screening.  The US Public Health Service and Infectious 
Disease Society of America recommend women with a history of cervical cancer or in utero 
exposure to diethylstilbestrol (DES) follow the same screening guidelines as average-risk women 
before age 30 years, and continue with that protocol after age 30 years. Women who are 
immunocompromised by organ transplantation, chemotherapy, chronic corticosteroid treatment, 
or who are human immunodeficiency virus (HIV) positive should be tested twice during the first 
year after diagnosis, and annually thereafter.  There is no specific age to stop screening for 
women with a history of cervical cancer, with in utero exposure to DES, and who are 
immunocompromised.  Women in these risk groups should continue cervical cancer screening 
for as long as they are in reasonably good health and would benefit from early detection and 
treatment (Smith et al., 2010).  
In November 2009, ACOG presented their updated guidelines for cervical cancer screening 
that recommended screening beginning at an older age and longer screening intervals for women 
in all age groups.  According to ACOG’s Cervical Cytology Screening (2009) the significant 
changes in the new guidelines include a set age to begin screening regardless of age of onset of 
vaginal intercourse, a lengthening of the screening interval by one year, and the establishment of 
an age to stop screening if there is a 10-year history of normal screening tests.  
History of Vaccines 
All humans have some amount of natural immunity to disease and infection. Immunization 
is the process of artificially creating immunity by deliberately infecting a person so the body 
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learns to protect itself (Waterson, 1978).  A vaccine causes the body’s immune system to 
produce antibodies to fight a modified form of the virus that is not harmful.  Then, if the person 
encounters the real and dangerous virus, the body is able to protect itself (Waterson, 1978).  
The concept of immunization, or how to artificially induce the body to resist infection, 
received widespread recognition in 1796, when British physician Edward Jenner inoculated a 
young boy in England and successfully prevented him from getting smallpox.  Jenner used a 
lancet to scratch infected material from a woman with cowpox which is very similar to smallpox, 
under the boy’s skin (Riedel, 2005).  
Vaccines work in the same manner and deliver minute amounts of substances that provoke 
antibody responses called antigens.  Antigens multiply more slowly and for a shorter period of 
time than their disease-producing counterparts.  As a result, the body recognizes just enough 
antigens to develop protective antibodies (CDC, 2009).  Today there are 15 different vaccines 
children may receive prior to their 21st birthday (Immunization Action Coalition, 2010) 
HPV Vaccine  
 The quadrivalent human papillomavirus  vaccine Gardasil® developed by Merck 
Pharmaceuticals for females prevents infection from serotypes  6, 11, 16, and 18, which are the 
four most common serotypes of human papillomavirus associated with the development 
of cervical cancer, genital warts, and some less common cancers (CDC, 2008).  The HPV 
vaccine Gardasil® protects against two of the HPV types 16 and 18 that cause approximately 
70% of all cervical cancer.  In addition, the quadrivalent HPV vaccine also protects against two 
additional HPV types 6 and 11 that cause most genital warts (CDC, 2008).  It is the only vaccine 
which prevents against these four HPV types (CDC, 2008).   
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The safety and efficacy of the vaccine continues to be studied and documented.  In females, 
a four year evaluation of the prophylactic efficacy of the HPV vaccine in preventing low grade 
cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts, indicated sustained 
protection against low grade lesions attributable to vaccine HPV subtypes 6, 11, 16, and 18 and a 
substantial reduction in the burden of these diseases through 42 months of follow-up (Dillner et 
al., 2011).  In addition, researchers from the University of Massachusetts conducted an extended 
literature search on the safety and efficacy of the HPV quadrivalent vaccine.  These researchers 
reviewed multiple bibliographic databases and concluded the vaccine was effective in the 
management of HPV by preventing vaccine subtype-related persistent infection and 
precancerous lesions.   
Research by Giuliano et al. (2011)  on 4,065 healthy males 16-26 years of age from 18 
countries in a double-blind trail examined safety of the HPV vaccine against active HPV types 6, 
11, 16, and 18 and efficacy in preventing the development of external genital lesions and 
anogenital HPV infection in boys and men.  The primary efficacy objective was to show that the 
quadrivalent HPV vaccine reduced the incidence of external genital lesions related to HPV-6, 11, 
16, or 18.  The conclusion of this study was quadrivalent HPV vaccine prevents infection with 
HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 
years of age. 
The vaccine was also regarded as generally safe and well-tolerated, based on an assessment 
of reported adverse events submitted through governmental databases and analyzed by 
independent researchers (Pomfret, Gagnon, Jr., & Gilchrist, 2011). 
On October 16, 2009, the FDA licensed bivalent HPV Cervarix® manufactured by 
GlaxoSmithKline pharmaceuticals for use in females aged 10 through 25 years. Cervarix® is the 
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second HPV vaccine licensed for use in females in the United States and contains two HPV types 
rather than four types like the Gardasil® vaccine.  It is not licensed for males.  It protects against 
HPV types 16 and 18, the causes of most cervical cancers (MMWR, 2010).  Cervarix will not be 
included in this research because it is not covered by the VFC program. 
Public health officials in the United States recommend vaccination of young women against 
HPV noting that as many as 80% of American women will have contracted at least one strain of 
HPV by age fifty (Dunne et al., 2007).  In 2000, genital HPV cost the nation $2.9 billion in direct 
medical costs (Chesson, Blandford, Gift, Tao, & Irwin, 2004).  Since neither vaccine covers all 
high-risk types of HPV, experts continue to recommend regular Pap smear screening even after 
vaccination (NCI, 2010; Markowitz et al., 2007).   
The ACIP recommends the HPV vaccine be administered to females by intramuscular 
injection in the upper arm.  The recommended schedule is a three-dose series with the second 
dose administered two months after the first dose. The third and last dose is given six months 
after the first dose.  The recommended age for vaccination of females is 11-12 years.  The 
vaccine can be administered to girls as young as 9 years old. Catch-up vaccination is 
recommended for females aged 13-26 years who have not been previously vaccinated 
(Immunization Action Coalition, 2010). 
A recommendation from the American Academy of Pediatrics was made in 2007 (AAP, 
2007) recommending the vaccine to the pediatrician’s female patients.  The American Academy 
of Family Physicians followed and recommended the vaccine to their female patients in 2007 
(Goeser, 2007).  
Until this time, the HPV vaccine was licensed only for young females. It was not until 
October 16, 2009, that the FDA licensed quadrivalent human papillomavirus vaccine, Gardasil® 
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as the only HPV vaccine for use in males 9 to 26 years for prevention of genital warts caused by 
human papillomavirus types 6 and 11. (MMWR, May 28, 2010).   Efficacy and safety of the 
vaccine for males in preventing the development of external genital lesions and anogenital HPV 
infection was performed on male’s age 16 to 26 years (Giuliano et al., 2011).  Their research 
indicated the quadrivalent HPV vaccine reduced the incidence of external genital lesions related 
to HPV subtypes 6, 11, 16, or 18, and reduced the development of related external genital lesions 
in males 16 to 26 years of age. 
After FDA approval, and on October 21, 2009, the ACIP provided guidance stating the HPV 
vaccine may be given to males aged 9 through 26 years to reduce their likelihood of acquiring 
genital warts.  The ACIP did not recommend the HPV vaccine for routine use among males. 
Instead, the committee voted to support the "permissive use" of the HPV vaccine among males, 
leaving decisions on whether to immunize males ages 9-26 years who request the vaccine to the 
discretion of their health care professional (MMWR, May 28, 2010).  In December 2010, The 
FDA also approved the HPV vaccine Gardasil® for the prevention of anal cancer and associated 
precancerous lesions due HPV sub types 6, 11, 16, and 18 in both males and females age 9 
through 26 years (FDA, 2010).   
The ACIP recommends the HPV vaccine be administered to males by intramuscular 
injection in the upper arm.  The recommended schedule is a three-dose series with the second 
dose administered two months after the first dose. The third and last dose is given six months 
after the first dose. The recommended age for vaccination of males is 11-12 years.  The ACIP 
allows the vaccine to be administered to those as young as age 9 years and through age 26 
(MMWR, May 28, 2010).  
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Barriers Related to HPV Vaccine Administration 
Research shows many important links between barriers and intention to vaccinate and how it 
affects vaccination rates.  The causal relationship between HPV and cervical cancer is a 
relatively recent discovery with clinical trials for the vaccine beginning in the 1990’s (Markowitz 
et al., 2007).  Since its discovery in 1956, HPV has been intensely studied.  Physician and 
scientist Harald zur Hausen first postulated in 1983 that HPV caused cancer in women (zur 
Hausen, 1996).  Zur Hausen (1996) was able to unveil HPV’s novel properties and proved that 
two HPV subtypes (16 and 18) could cause as much as 70% of cervical cancer cases.   In 2008, 
zur Hausen received the Nobel Prize for his work on HPV (Nobel Prize, 2008). 
As detailed in a systematic review by Allen et al. (2010), most research on this topic was 
conducted prior to vaccine licensure in 2006.  In their review, it was noted that at least two-thirds 
of existing U.S. studies and 36% of non-U.S. studies were conducted prior to HPV vaccine 
licensure.  With this consideration, barriers to HPV vaccination will be summarized below. 
Informational Barriers 
Lack of information and education is identified by many researchers as a barrier to HPV 
vaccination.  Information and education barriers for young women, parents of adolescent girls, 
and physicians are well documented (Chan, Cheung, Lo, & Chung, 2007; Mays, Sturm & Zimet, 
2004; Olshen, Woods, Austin, Luskin, & Bauchner, 2005; Woodhall, 2007).  Multiple studies 
suggest parents and young women often are not aware of the risks of contracting HPV or its 
direct association to cervical cancer (Chan, Cheung, Lo, & Chung, 2007; Dempsey & Davis, 
2006; Gerend, Lee, & Shepherd, 2007; Hoover, Carfioli, & Moench, 2000).  Lack of information 
may also impede physicians from recommending the vaccine if they are not aware of the benefits 
of vaccination, or how to educate about the benefits of the vaccine.  In a New Mexico study 
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involving 37 primary care providers, researchers revealed barriers to counseling parents on HPV 
vaccination included limited knowledge of HPV and low levels of knowledge by adolescents 
(Sussman et al., 2007).  Throughout the literature, researchers recommended continued 
educational outreach and interventions for parents, women, and physician healthcare providers.  
Safety and Efficacy Barriers 
There are concerns by physicians, parents, and young women, about vaccine safety and 
efficacy.  According to published research, there have been more than 26 million doses of the 
HPV vaccine distributed in the United States with 12,424 reports of adverse reactions.  Most 
adverse events rates were no greater than background rates compared with other vaccines, but 
there was disproportional reporting of syncope and venous thromboembolic events with the HPV 
vaccine (Slade et al., 2009).  
In a study of 513 pediatricians using a traditional mail survey, pediatricians reported 
concerns about the safety of the vaccine and uncertainty regarding the efficacy of the vaccine in 
terms of lifetime protection for individuals (Kahn et al., 2005).  In an editorial in the Journal of 
American Medicine, Gostin and DeAngelis (2007) caution physicians to consider the lack of 
adequate efficacy trials for girls aged 9 to 15 and recommend more trials be completed before 
mandating the vaccine for school enrollment.  Other concerns by parents and young women 
focus on potential harmful side effects from the vaccine and the general safety of the vaccine 
(Gerend et al., 2007; Marshall, Ryan, Roberton, & Baghurst, 2007; Woodhall et al., 2007).  
Cultural Barriers 
Cultural barriers in the literature focus on race, ethnicity, socioeconomic status, education 
level and health insurance status (Sussman et al., 2007).  According to the American Cancer 
Society (2009), Latinas have higher cervical cancer age-adjusted incidence and mortality rates, 
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and present with more advanced disease compared to non-Latino whites.  Research to determine 
HPV awareness among Latina immigrants and Anglo women in the southern United States 
suggested Mexican and Honduran women were less likely to be aware of HPV and the HPV 
vaccine, and more likely to be uninsured and without a regular health care provider than Anglo 
women (Luque et al.,  2010).  
In a study of Hispanic women in New Mexico that included a series of focus groups, 
participants indicated physicians should consider relevant cultural issues (Vanslyke et al., 2008).  
The researchers noted Hispanic men may put their sexual partners at heightened risk for HPV 
due to cultural tolerance of refusing to wear condoms and engaging in sexual activities outside of 
a committed relationship.  In another qualitative research study with Hispanics conducted in 
south Georgia for the purpose of developing cervical cancer education curriculum for lay health 
worker outreach, study participants reported cultural barriers for cervical cancer screening, 
primarily regarding feelings of embarrassment, and not having permission from their husbands to 
go to the clinic (Luque, et al., In Press).   
In a qualitative study, Tissot et al. (2007) found pediatricians had concerns about parents’ 
anti-vaccination beliefs, particularly parents who have strong religious beliefs or who believe in 
holistic approaches to healing.  This study noted African Americans were less trusting of 
physicians and vaccines.  The study also reviewed socioeconomic factors and suggested lower 
education and income may decrease parental ability for those who seek vaccination.  However, 
the study also suggested those with higher income and education may not consider their children 
vulnerable and so would be less willing to seek vaccination.  Issues of higher income and lower 
education status were found to be barriers to intentions in other studies as well, regardless of race 
(Hopenhayn et al., 2007; Woodhall et al., 2007).  
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Psychological Barriers 
Psychological barriers are barriers associated with personal concerns with HPV vaccination. 
These barriers are placed in two broad categories.  The first category is concerns by the 
vaccinating physicians regarding attitudes of parents toward the vaccine that prevents an STD, 
and obtaining parental consent (Dempsey & Davis, 2006; Kahn et al., 2005; Sussman et al., 
2007).  The second category is by parents of young women.  The parental concern is that HPV 
vaccination encourages promiscuity.  Another concern in the parental category is the perception 
of there being little personal risk of HPV infection for their children (Brewer & Fazekas, 2007; 
Marshall et al 2007; Woodhall, et al., 2007). 
Financial Barriers 
The HPV vaccine, Gardasil®, is the most expensive vaccine recommended for children and 
adolescent with a reimbursement cost of $360, compared with other recommended vaccines that 
are less than $50.00 (Gudeman, 2007).  Women with health insurance report this does not 
necessarily make the HPV vaccine affordable if their health insurance plan does not cover the 
cost (Hopenhayn et al., 2007).  As a result, some physicians report keeping their vaccine 
inventory low and will only offer it to those patients whose coverage will provide reimbursement 
(Daley, 2006; Gudeman, 2007).  
This upfront or initial cost of purchasing HPV vaccine places a significant financial burden 
on physicians who must purchase it for their patients with insurance or otherwise do not qualify 
for the federal and state Vaccine for Children (VFC) immunization program.  The VFC program 
provides free vaccines to qualifying children based upon income (Dempsey & Davis, 2006).  
Indeed, Gudeman (2007) notes that while the VFC program offers vaccine at no cost to 
underinsured adolescents, there is limited access to VFC discounts if the physician is not part of 
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the VFC program.  There is further limited access if there is a lack of presence of Federally 
Qualified Health Centers or a Rural Health Clinics in the geographic area.  
Religious Barriers 
Cultural considerations which include religious beliefs and implication toward vaccination 
have been studied by many (Askelson, 2010; Borrayo & Jenkins, 2003; Chan et al., 2007; Charo, 
2007; Daley et al., 2006; Katz et al., 2009; Hoover et al., 2000; Tissot et al., 2007).  Their 
research suggests strong religious beliefs lead to a delay of vaccine administration until an older 
age or omitting the vaccine altogether.  According to qualitative review of the relevant literature 
by Zimet (2005), religious conservatives voiced concern that allowing their daughters to receive 
the vaccine undermines abstinence teaching.  This argument is similar to that used against 
school-based sex education programs and condom distribution (Zimet, Shew, & Kahn, 2008). 
Compliance Barriers 
 The HPV vaccine is the only vaccine offered to older children and requiring a three-dose 
series (McIntosh, Sturpe, & Khanna, 2008).  This may present a compliance challenge for some 
female patients.  Patients particularly vulnerable are those populations with limited access to 
transportation or who must take off work repeatedly to complete the three dose series (Herzog, 
Huh, Downs, Smith, & Monk, 2008).  In addition, this older age group does not have as much 
routine contact with physicians as when they were younger and receiving medical visits for 
growth and development monitoring.  In Georgia, and according to the Medicaid periodicity 
schedule of visits, physicians are reimbursed for one annual health check visit during 
adolescence.  Other visits to the physician must be a problem focus visit to qualify for 
reimbursement ("Health check services", 2007; McIntosh et al., 2008).  Most insurance 
companies follow this guideline and limit the number of routine office visits. Requiring three 
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visits for the vaccine series can place an added burden on both patient and physician in terms of 
scheduling, vaccine availability, and the above noted limits placed on the number of visits 
covered for adolescent well-visits by insurance and other third party reimbursement programs.   
Reimbursement and getting to the physician’s office are not the only compliance barriers.  
Other researchers found completing the vaccine three dose series to be a barrier even when the 
vaccine was provided within a school setting, as students missed their scheduled appointments 
(Brabin et al., 2008).  This same study also found uptake was significantly lower in schools with 
a higher proportion of ethnic minority girls or if there was a higher proportion of girls entitled to 
free school meals (Brabin et al., 2008). 
Supports Related to HPV Vaccination 
Similar to barriers, there are supports noted in the literature that encourage HPV vaccination. 
Financial supports and health behavior were reported most often as supports (Kahn et al., 2008; 
Spereber, Brewer, & Smith, 2008).  Other common supports included in the literature comprise 
physician recommendations and organizational supports (Kahn et al., 2009; McCave, 2010). 
Supports to HPV vaccination will be discussed in greater detail in the following sections. 
Financial Supports 
The financial burden of the HPV vaccine has been a concern for patients of lower socio-
economic status and providing financial support to physicians and patients is important. 
Physicians, women, and parents indicate that having the vaccine covered fully by insurance is 
necessary, as is making it affordable for those without insurance (Kahn, et al., 2005; Hoover et 
al., 2000).  
The most significant financial support is the inclusion of the HPV vaccine in the VFC) list 
of federally covered vaccines.  The CDC’s Section 317 Grants Program is the main source of 
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funding for state immunization programs.   States use these federal funds to pay for underinsured 
patients to cover their vaccine costs under Section 317 of the Vaccination Assistance Act of 1962 
(Rein, Honeycutt, Rojas-Smith, & Hersey, 2006; Institute of Medicine, 2003).  
The VFC program is a federal entitlement program established in 1994.  Research published 
in the Journal of American Medical Association, notes that VFC funds account for 
approximately 43% of vaccine expenditures (Lee et al., 2007).  The VFC program provides free 
immunization services to uninsured and underinsured children up to age 19 to participating 
physicians, Federally Qualified Health Centers and Rural Health Clinics (Institute of Medicine, 
2004).  Once the ACIP adds a vaccine to the recommended childhood/adolescent immunization 
schedule and votes to include the vaccine for use under the VFC program, the vaccine must be 
subsidized under VFC for qualified children (Orenstein, Rodewald, Hinman, 2004).  Parents who 
support a mandatory HPV vaccination are aware of the VFC program and how it could improve 
coverage for those with limited financial resources (Ferris, Horn, & Waller, 2010). 
The Georgia VFC program, which began October 1994, is coordinated by the Georgia 
Immunization Program within the Division of Public Health through the Department of 
Community Health (Georgia Department of Community Health, 2010).  Georgia’s VFC Program 
provides free vaccines to private and public providers including physicians, for children up to 18 
years old who are Medicaid-eligible, American Indian/Alaska Native, uninsured, and 
underinsured (Immunization in Georgia, 2009).  As of December 2004, 3,062 private physicians 
at 1,025 locations participate in the VFC program in Georgia (Immunization in Georgia, 2009).  
A study of adosescent girls enrolled in the Florida Medicaid VFC Program, which offers the 
HPV vaccine, indicated  girls in this program were more likely to have initiated the HPV vaccine 
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series if the financial barrier of cost was removed (Staras, Vadparampil, Haderxhanai, & 
Shenkman, 2010). 
Organizational Supports 
Organizational supports provided by primary care settings such as clinics and private 
practices have been discussed in the literature (Bhatla et al., 2010; Chao, Velicer, Slezak, & 
Jacobsen, 2010; Humiston et al., 2009).  Creating physician office supports, such as decreasing 
time constraints and providing information  to parents, was found to be effective (Chan et al., 
2007).  
In a qualitative study of 31 pediatricians by Tissot et al. (2007), potential supports for 
improving HPV vaccination were considered.  The findings for supports included a number of 
strategies that pediatricians believed were critical for effective future implementation of HPV 
vaccination. These included: 1) maximizing ease of vaccine administration; 2) implementing 
office-based procedures and policies to optimize vaccine uptake; 3) ensuring broad access to 
vaccines; 4) ensuring endorsement of vaccination by influential organizations; and 5) addressing 
the educational needs of providers, parents, and patients (Tissot et al., 2007, p. 124).  Supports 
included providing lectures and written materials, such as information sheets and professional 
organization policy materials.  Other supports included hosting local expert guest speakers, 
directing patients to informational web sites and providing data on HPV prevalence and 
susceptibility, HPV-related diseases, and health impact and devising strategies for talking with 
parents and youth in a culturally sensitive way were also incorporated (Tissot et al., 2007).   
In Georgia, a statewide web portal internet system is able to assist providers who administer 
vaccine by allowing them to access vaccine information on any individual who has received a 
vaccine in Georgia.  The Georgia Immunization Registry law was passed in 1996 and the 
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Georgia Registry of Immunization Transactions and Services (GRITS) were introduced 
statewide to include vaccination history on childhood vaccines in May 2003.  It was expanded by 
House Bill 1526 in 2004 to require reporting by any person who administers a vaccine or 
vaccines licensed for use by the FDA, to a person from birth to death, be recorded in the GRITS 
statewide vaccine registry (Georgia General Assembly, 2004). 
Among other benefits, the internet based GRITS immunization registry allows enrolled 
physicians and other providers, both public and private, to input and access any individual’s 
complete immunization record.  This access decreases over and under immunization, and 
provides a current picture of the immunization status of all Georgians including that of the HPV 
vaccine.  The benefits are beginning to be realized as the GRITS registry is used in population-
based research for children behind schedule in receiving immunizations and provides a reminder 
to those who require the second and third dose of a series immunization such as the HPV vaccine 
(DHR - Immunization in Georgia, 2006). 
Physician Recommendation as a Support 
HPV vaccine acceptability by parents and young women is greater when they perceive that 
their health provider recommends the vaccine (Gerend et al., 2007; Tedeschi et al., 2006).  
Indeed Sussman et al. (2007) listed four factors important in the counseling process: 1) the 
importance of rapport building with adolescents; 2) the assumption that adolescents will engage 
in high-risk behaviors; 3) the difficulty and complexity of counseling about the HPV vaccine; 
and 4) the attitudes of primary care providers, nurse practitioners, and community acceptance of 
the HPV vaccine.  In a national survey of pediatricians by Daley et al. (2006), respondents were 
more likely to recommend HPV vaccination to older compared to younger adolescents.  They 
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further noted respondents were more likely to recommend vaccine to female versus male patients 
(Daley et al., 2006, p. 2284).  
McCave (2010) noted supports necessary for improving HPV vaccination rates include a 
personal belief in the positive impact of the HPV vaccine. This was followed by providers 
feeling comfortable talking with parents about the sexual nature of diseases prevented by the 
vaccine, and the importance of adhering to the CDC's recommendations on HPV vaccination.  
McCave further noted age of the patient likely influenced the providers' HPV vaccination 
behaviors, particularly if parents have concerns about vaccinating their pre-adolescent child.  She 
concluded her finding by stating providers can best serve their patients when they are aware of 
the potential barriers and supports that may influence their HPV vaccination behaviors. 
In a study of physicians currently administering the vaccine to females, findings suggest 
physicians supported the concept of vaccinating males for the benefits it imparts on both sexes. 
The physicians in the study agreed a gender-neutral HPV vaccination recommendation would be 
appropriate with regard to public health but were less sure that such a recommendation would 
change patient or parental attitudes toward HPV vaccination or improve current HPV vaccination 
efforts (Weiss, Zimet, Rosenthal, Brenneman, & Klein, 2010). 
State Law and the HPV Vaccine Mandate for School Admission 
In a report by the Institute of Medicine, state immunization programs, including Georgia, 
have seen an increase in the number of new and expensive vaccines (Institute of Medicine, 
2003).  The newer vaccines improve the health of the child immunized and prevent many 
diseases that were once common to childhood.  However, according to the latest price lists 
published by the CDC,  the total cost dose to fully vaccinate a child in Georgia at a physician’s 
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office has risen from $155.00 in 1995 to over $1,200.00 in 2010 (CDC Pediatric/VFC Pricelist, 
2010).  
Historically, the preservation of the public’s health has been the responsibility of state and 
local governments, and the authority to enact laws relevant to the protection of the public health 
derives from the state’s general police powers (Gostin, 2008).  All states in the United States 
have mandated various types of vaccines for school-aged children.  The most persuasive case for 
a mandate is when the vaccine prevents a serious infectious disease spread by casual contact in 
the age group for which it is mandated.  Examples of mandated vaccines in this category are 
those that protect against polio, measles, mumps, rubella, diphtheria, and pertussis. Exemptions 
to vaccinations are available in cases of religious convictions. However, widely used vaccine 
exemptions result in a lowering of what epidemiologists refer to as "herd immunity," and result 
in an increase in disease (CDC, 2006). 
In February 2007, Texas became the first state to mandate the HPV vaccine for girls 
entering sixth grade.  Texas legislators were not supportive and by May 2007 passed a bill 
reversing the governor's order for the mandate and instead mandated that no HPV vaccine could 
be ordered for schoolchildren over the next four years (Javitt, Berkowitz, & Gostin, 2008). 
During this same time, a cross-sectional, web-based survey of Texas physicians was conducted 
to determine three outcome variables pertaining to HPV vaccination. These were: HPV vaccine 
recommendations to 11-to-12-year-old girls, probability of recommending the vaccine to 11-to-
12-year-old boys, and agreement with the mandated vaccination of 11-to-12-year-old girls.  Of 
the 1,122 respondents to the survey, over half of physician respondents did not follow current 
recommendations for universal HPV vaccination of 11-to-12-year-old girls (Kahn et al., 2009).  
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In Georgia, lawmakers determined the HPV vaccine does not meet the high threshold 
necessary for school entry.  Namely, HPV is spread by sexual or very close contact and therefore 
is not an epidemic infectious disease among school-aged children requiring it to be a mandated 
vaccine (National Conference of State Legislatures, 2010).  Therefore the state of Georgia does 
not mandate the HPV vaccine as a required vaccine for school admission (Georgia Department 
of Education, 2010).  
Georgia Public Health Districts 
 Georgia Department of Community Health, Division of Public Health is the lead division 
entrusted by the people of the State of Georgia with the ultimate responsibility for the health of 
communities and the entire population. At the state level, the Division of Public Health is 
divided into numerous branches, sections, programs and offices (Georgia Department of 
Community Health, 2010). At the local level, the Division of Public Health functions through 18 
health districts which contain the 159 county health departments (Appendix A).  
The Immunization Section of the Division of Public Health works collaboratively with 
public and private providers, advocacy groups, and other stakeholders, to increase immunization 
rates for all Georgians and decrease the incidence of vaccine-preventable diseases.  Each of the 
159 counties has some public health presence and the ability to administer the HPV vaccine. 
According to Dr. Anil T. Mangla, Director of the Immunization Section of the Division of 
Public Health, a population-based study conducted in Georgia in 2004 showed most childhood 
immunizations (70%) were administered in the private sector at the physician office, while 14% 
were administered by county health departments.  The sources for 16% were unknown though 
some were expected to be Federally Qualified Health Centers located in low income areas (A. T. 
Mangla, personal communication, October, 2010).  A Georgia immunization study conducted in 
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2007 revealed that most childhood immunizations (81%) were administered in the private sector 
at the physician office, while county health departments immunized 9.8%, and the sources for 
9% were unknown, indicating more children are receiving vaccines at physician offices (Georgia 
Department of Community Health, 2010).  The Georgia Division of Public Health does not 
record information on physician HPV vaccination administration rates.  However, according to a 
CDC report, Georgia physicians vaccinate one in three females eligible for HPV (MMWR, 
2009).  As the Mission and Vision of the Immunization Section of the Division of Public Health 
is to “… work to increase immunization rates for all Georgians and decrease the incidence of 
vaccine-preventable diseases,” it is important that the Immunization Section of the Division of 
Public Health have information about the attitudes and beliefs of Georgia physicians toward 
administering the HPV vaccine and assess perceived knowledge, barriers, practices, and 
adherence to ACIP guidelines and recommendations regarding HPV vaccination. 
Urban and Rural Classification of Georgia Counties 
This research sought to determine differences between urban and rural physicians’ 
administration and recommendation of HPV vaccine.  According to a health care workforce 
report commissioned by the U.S. Department of Health and Human Services, it was noted 
Georgia’s rural population lacked adequate geographical access to basic health care services 
(Bureau of Health Professions, 2011).  According to their report, the percent of Georgia’s 
population residing in primary care federally-designated health professional shortage areas 
(HPSAs) exceeds the national proportion.   Rural areas continue to have difficulty recruiting 
primary care physicians and Georgia’s community health centers in underserved areas voice 
growing concerns about their difficulty recruiting and retaining physicians (Bureau of Health 
Professions, 2011). 
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As this present research sought to determine differences between urban and rural physicians’ 
administration and recommendation of HPV vaccine, the terms urban and rural had to be defined 
to determine if differences emerged between vaccination rates in rural or urban defined areas.  
Rural is an imprecise term that can mean different things to different researchers.  For example, 
what is considered rural in one state with low population density may not be considered rural in 
another state with a much higher density.  However, for the purposes of this proposed research, 
there is a need for exact definitions of what is meant by "rural." 
Government agencies considered whose definitions of what is rural or urban include: 1) the 
U.S. Census Bureau; 2) the Office of Management and Budget; 3) the Economic Research 
Service of the U.S. Department of Agriculture (USDA); and 4) the Georgia Office of Rural 
Health. 
According to the U.S. Census Bureau, specific urban entities are defined as an urbanized 
area and include an urban nucleus of 50,000 or more people.  Individual cities with a population 
of 50,000 may or may not be contained in an urbanized area.  Urbanized areas have a core with a 
total land area less than two square miles and a population density of 1,000 persons per square 
mile.  They may contain adjoining territory with at minimum 500 persons per square mile and 
encompass a population of at least 50,000 people.  An urban cluster also has a core as identified 
above with a total land area of less than two square miles and a population density of 1,000 
persons per square mile.  They may contain adjoining territory with at minimum 500 persons per 
square mile and encompass a population of at least 2,500 but less than 50,000 persons (United 
States Census Bureau, 2010).  
A second definition of rural is offered by the Office of Management and Budget, which 
defines metropolitan statistical areas - or metro areas - as central or core counties with one or 
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more urbanized areas, and outlying counties that are economically tied to the core counties as 
measured by work commuting (Office of Management and Budget, 2010).  They include 
outlying counties if 25% of workers living in the county commute to the central counties, or if 
25% of the employment in the county consists of workers coming out from the central counties-
the so-called "reverse" commuting pattern.  Non-metro counties are outside the boundaries of 
metro areas and are further subdivided into two types.  
The Office of Management and Budget use the term “Micropolitan statistical areas “or 
“micro areas” to denote non urban areas.  These are non-metro counties with an urban cluster of 
at least 10,000 persons or more (Office of Management and Budget, 2010).  The last type is the 
noncore county.  Researchers and others who discuss conditions in rural America often refer to 
nonmetropolitan areas that include both micropolitan and noncore counties as rural areas (Office 
of Management and Budget, 2010; Rural Assistance Center, 2010). 
A third definition is through the offices of The Economic Research Service. This includes 
the United States Department of Agriculture (USDA), the Department of Health and Human 
Services, Health Resources and Service Administration's Office of Rural Health Policy along 
with Rural Health Research Center, and the University of Washington which collaborated to 
develop the Rural-Urban Commuting Area system.  Their definition is a census tract-based 
classification that utilizes the Bureau of Census urbanized area standard and place definitions in 
combination with commuting information to characterize rural and urban status of census tracts 
(United States Department of Agriculture Economic Research Center, 2010).  
The fourth and final definition is used by the Georgia Office of Rural Health.  The Georgia 
Office of Rural Health defines a Georgia rural county as any county having a population of less 
than 35,000 according to the U.S. Census of 2000 (Rural Assistance Center, 2010).  Since this 
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study involved research pertaining to possible differences between urban and rural HPV vaccine 
administration of Georgia physicians by county, this study will use the Georgia Office of Rural 
Health Classification for rural counties.  Therefore, those counties with less than 35,000 will be 
classified as rural and those with greater than or equal to 35,000 will be classified as urban. 
Use of Theory 
This study relied upon theory to inform the development of the research questions and 
interpret the findings.  Health improvements, such as providing HPV vaccination to one’s 
patients, cannot be completed by simply providing the physician with information and raising his 
or her awareness to the need to educate parents about HPV.    
Indeed, ecological models suggest that multiple levels must be in place for change to occur.  
Stokols (1996) notes successful health improvement and promotion programs must link 
behavioral strategies with efforts to strengthen environmental supports within the broader 
community that are conducive to well being.  Using the social ecological approach, there are 
alternative yet complementary perspectives.  The social ecological model considers the complex 
interplay between individual, relationship, community, and societal factors by allowing us to 
address the four factors, or levels that put people at risk (Stokols, 1996).   
The first level looks at the broad societal factors that help create a climate in which HPV 
vaccination is encouraged or inhibited. These factors include social and cultural norms. Other 
large societal factors include the health, economic, educational and social policies that help to 
maintain economic or social inequalities between groups in society (Stokols, 1996).  
The second level explores settings such as the physician workplace, and organizations in 
which social relationships occur.  It also seeks to persuade or dissuade providing HPV 
vaccination. 
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The third level encompasses relationships with peers, professional partners, and family 
members.  Factors include whether or not other trusted physicians are providing the vaccine, and 
if valued sources of information such as professional journals and associations, encourage 
vaccination.  
The first level, or individual level, identifies biological and personal history factors.  In this 
research, factors associated with the first level include age, education, and personal feelings 
toward HPV vaccination.   In this level, the Precaution Adoption Process Model was explored to 
determine if it would inform the research undertaken. 
The Precaution Adoption Process Model was first suggested by Weinstein (1988) as a model 
used to describe and explain the process by which people adopt precautions against a new risk. 
For example, a risk that they have recently learned about rather than a risk they have been aware 
of for some time.  It is applicable in the situation where a new precaution against an "old" risk 
becomes available such as the introduction of the HPV vaccine to prevent cervical cancers and 
genital warts. 
The Precaution Adoption Process Model specifies seven discrete stages.   It defines the 
stages without reference to arbitrary time periods and, between having never thought about 
adopting a particular precaution and having thought about it and decided not to act.  In each stage 
the types of information and interventions needed to move people closer to action varies 
(Weinstein, 1988).  One advantage of such a stage theory is that it useful when the same 
population is being surveyed over time or targeting interventions to move people through stages.  
It was not used in this research as the survey was administered once and follow up surveys to the 
sample were not part of this research.  Next, the health belief model was explored to inform this 
research.   
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Health Belief Model  
The central premise that a primary care provider’s perceived barriers and benefits of 
providing HPV vaccine to her clients, which stem from the physician’s personal or normative 
beliefs as well as perceived severity and susceptibility of diseases associated with the human 
papillomavirus, and her recommendation and administration of the vaccine is the foundation for 
this study.   
The Health Belief Model was created to provide a framework to better understand why some 
people take actions to avoid illness, whereas others do not (Becker, 1974). This model was 
developed by social psychologist researchers with the U.S. Public Health Service in the early 
1950s (Becker, 1974; Champion & Skinner 2008; Rosenstock, 1974).  The U.S. Public Health 
Service researchers were motivated to study why people sought radiographic examinations for 
tuberculosis and why others did not.  They created a theory that attempted to explain and predict 
given health-related behavior from certain patterns of belief about the recommended health 
behavior and health problems that the behavior was intended to prevent or control.  The model 
postulates that the following conditions both explain and predict a health-related behavior: 
1. A person believes their health is at risk or their chances of getting a condition.  For the 
behavior of seeking screening or treatment, the person must believe that he/she can have 
the disease yet not feel symptoms.  This collection of beliefs is referred to as "perceived 
susceptibility." 
2. The person perceives the potential seriousness of the condition in terms of pain or 
discomfort, time lost from work, economic difficulties, or other negative outcomes.  This 
belief is referred to as “perceived severity.” 
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3. On assessing the circumstances, the person believes that benefits derived from the 
recommended behavior (such as obtaining an immunization) outweigh the costs and 
inconvenience and that they are indeed possible and within her ability to acquire.  These 
perceived or anticipated benefits and costs are referred to as “perceived benefits.” 
4. Before taking action, the person must determine the tangible and psychological costs of 
the action and barriers.  Then the barriers must be reduced through reassurance, 
incentives and/or assistance.  This is referred to “perceived barriers.” 
5. The person receives strategies to act or a precipitating force that makes the person feel 
the need to take action.  This is referred to “cues to action.” 
6. Finally, the person must have confidence is their own ability to take action.  This final 
step is referred to as “self-efficacy.” 
The model soon changed shape when applied to other health problems such as seeking 
immunization and attempted to more broadly define people's different responses to public health 
measures and their use of health services.  In these wider applications, the model substituted a 
belief in susceptibility to a disease or health problem for the more specific belief that one could 
have a disease and not know it, which had been featured in Godfrey Hochbaum's original study 
as the most important belief accounting for seeking screening examinations (Breslow & 
Cengage, 2002; Champion & Skinner, 2008). The Health Belief Model was selected to inform 
the development of the research questions and interpretation of results.  See Table 1 for Health 
Belief Model constructs and it application to this research of the HPV vaccination. 
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Table 1: 
  Health Belief Model and HPV 
Health Belief Model Component 
 
HPV vaccination counterpart 
 
Perceived susceptibility 
 
 
Knowledge that the patient is at risk for HPV infection. 
 
Perceived severity 
 
Knowledge that HPV can become a serious illness leading to genital 
warts, cervical and other cancer. 
 
Perceived benefits 
 
Knowledge that the vaccine reduces risk of  
HPV  
 
Perceived barriers 
 
Fear of inadequate reimbursement, inability to complete series, and 
parental barriers surrounding the vaccine 
 
Cues to action 
 
Scheduling healthcare visits for the patient to obtain the HPV vaccine 
through telephone call back, reminders, and parental education. 
 
Self-efficacy 
 
Confidence in belief that the physician is capable of administering the 
HPV vaccine  
 
Summary 
The human papillomavirus is the single most common sexually transmitted disease in the 
United States (Trottier, 2006).  On June 8th, 2006, the FDA approved Gardasil® by Merck 
Pharmaceuticals as the first HPV vaccine to protect women between the ages of 9 and 26 
(Markowitz et al., 2007).  Less than one year later, in 2007, the ACIP of the CDC recommended 
that all girls aged 11 and 12 be vaccinated against HPV, with the indication that girls as young as 
9 years of age, and older females between the ages of 13 and 26 may receive the vaccine. 
On October 16, 2009 the FDA approved the same HPV vaccine, for use in boys and men 9 
through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11 and for 
offering protection to their partners, making it the only HPV vaccine approved for use in males 
at this time.  The approved HPV vaccine protects against HPV types 6 and 11 which cause 
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approximately 90% of all genital warts cases (MMWR, May 28, 2010).  Since there is a high rate 
of transmission of HPV in female partners of men with pre-existing warts, and HPV infection in 
men has been shown to contribute to HPV infection and subsequent cervical disease and cancer 
in women, it is necessary to vaccinate both males and females to prevent the spread of the virus 
(Giuliano, 2007).  
The National Cancer Institute’s State Cancer Profile reveals Georgia with an estimated 364 
new cases of cervical cancer in 2006, with 122 deaths from the disease (State Cancer Profiles, 
2010).  Despite having this vaccine available, only 38% in Georgia have been vaccinated with at 
least one of the three doses that are necessary for HPV immunity (MMWR, 2010).  This study 
examined the prevalence of Georgia physician intention and administration of the HPV vaccine, 
to 11-12 year-old girls and intention to recommend the HPV vaccine, to 11-12 year old boys.  
For the purposes of this research, the quadrivalent human papillomavirus vaccine, Gardasil® was 
used as it is the only quadrivalent HPV vaccine currently available for commercial use and it is 
the only HPV vaccine approved by the VFC program for use in Georgia.       
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CHAPTER 2 
HYPOTHESES AND RESEARCH QUESTIONS  
Research Questions 
The following research questions were explored: 
Research Question #1: 
 
What barriers do Georgia physicians enrolled in the Vaccine for Children (VFC) program 
perceive when providing the Human Papillomavirus Virus (HPV) vaccine to their female 
patients? 
 
Research Question #2: 
 
What knowledge do the Georgia physicians enrolled in the VFC program have when providing 
the HPV vaccine to their female patients? 
 
Research Question #3:   
 
What percentage of Georgia physicians enrolled in the VFC program administers the HPV 
vaccine to their female patients according to Advisory Committee on Immunization Practices 
(ACIP) published guidelines by providing the vaccine to their 11 – 12 year old patients? 
 
Research Question #4: 
 
What percentage of Georgia physicians enrolled in the VFC program indicates they will 
recommend the HPV vaccine to their male patients? 
 
Research Question #5: 
 
What differences will emerge when the data are analyzed by urban vs. rural characteristics? 
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Hypotheses 
In addition, the following hypotheses were tested: 
Hypothesis #1: 
 
No statistical differences will be detected between the perceived barriers by physicians enrolled 
in the VFC program who provide the HPV vaccine to females, and geographic setting (urban vs. 
rural).   
 
Hypothesis #2: 
 
No statistical differences will be detected between the perceived knowledge of physicians 
enrolled in the VFC program who provide the HPV vaccine to females, and geographic setting 
(urban vs. rural). 
 
Hypothesis #3: 
 
No statistical differences will be detected between the percentage of Georgia physicians enrolled 
in the VFC program who administer the HPV vaccine according to ACIP published guidelines  
by providing the vaccine to their 11 – 12 year old patients and geographic setting (urban vs. 
rural). 
 
Hypothesis #4: 
 
No statistical differences will be detected between the percentage of Georgia physicians enrolled 
in the VFC program who indicate they recommend the HPV vaccine to male patients, and 
geographic setting (urban vs. rural). 
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CHAPTER 3 
METHODS AND MATERIALS 
Purpose of the Study 
The purpose of this study was to survey Georgia physicians enrolled in the VFC program to 
assess their perceived knowledge, barriers, practices and adherence to ACIP guidelines and 
recommendations of immunization of the quadrivalent HPV vaccine.  The Health Belief Model 
(Becker, 1974; Champion & Skinner, 2008; Glanz, Rimer, & Viswanath, 2008; Rosenstock, 
1974) was used to inform this study of Georgia vaccine administration in urban and rural 
locations. 
Design of the Study 
The study was approved by the Georgia Southern University Institutional Review Board 
prior to data collection in October 2010 (Appendix B).  The variables under study, perceived 
knowledge, barriers, practices, and adherence to ACIP guidelines were assessed via a cross-
sectional research design (Campbell & Stanley, 1966).  The intent was to provide researchers, 
Georgia Department of Community Health and Georgia Public Health with a comprehensive 
examination of the status quo with regard to compliance with recommended ACIP guidelines for 
vaccine administration in urban and rural locations. 
Sampling Plan 
The Georgia Immunization Section of the Division of Public Health located within the 
Department of Community Health was contacted in January 2010 and a request for a list of VFC 
providers who administer the HPV vaccine was submitted.  The request was granted by the 
acting program director in February 2010.  The VFC list included 1,807 providers throughout the 
state.  Upon examination of the list, it was determined that a physician provider on the list could 
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be a single provider practicing at one location or multiple providers practicing at one location.  In 
addition, it was determined not all provider locations were up to date, and others should be 
excluded.  Examples of those considered for exclusion included chain grocery stores which had 
clinics located within the grocery store and   provided influenza vaccines to the general public.  
The list was updated in March 2010 with the assistance of the Georgia Immunization Section 
within the Division of Public Health to contain only providers who administered vaccine at a 
physician setting.  The updated list contained 1,307 (N= 1,307) provider practice locations in 
each of the 159 counties in Georgia.  From this, a stratified sample where type of county was the 
strata was created from the VFC provider list.  The primary sampling unit was the county.  
Counties were selected via probability proportional to size (PPS) sampling.  Probabilities for 
each county were constructed based on the number of providers within a county, thus counties 
with more VFC providers had a higher probability of being selected for inclusion.  The 
secondary unit of sampling was the provider and all providers within a county were sampled.  As 
some providers represented more than one physician at a practice location, a question was 
included to determine how many physicians were located at that practice location (Appendix C).  
The final sampling frame included 389 (n = 389) provider locations.  Of these, 305 were located 
in six urban counties and 84 were in18 rural counties.  An attempt to contact the 389 provider 
locations was made.  Ninety five responded that they did not give the HPV vaccine in their 
office, 30 could not be contacted by telephone or email and 264 responded that  they 
administered the HPV vaccine in their office yielding a final sampling frame of 264 (n=264). 
Instrumentation 
The survey of physician perceived knowledge, barriers, practices and adherence to ACIP 
guidelines and recommendations of immunization of the HPV vaccine was designed based upon 
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previous research.  A modification of a previously validated survey tool developed by 
researchers from the H. Lee Moffitt Cancer Center and Research Institute (Moffitt) was used.  
The Moffitt survey was developed and tested by Vadaparampil and Kahn as part of review of US 
physicians and was part of a NIH funded four year project examining physician 
recommendations for the quadrivalent human papillomavirus vaccine in 11-12 year old girls, 
intention to recommend HPV vaccines to 11-12 year old boys, and attitudes about mandated 
HPV vaccination for 11-12 year old girls (Vadaparampil, 2009; Kahn et al., 2009).  That survey 
was structured to assess constructs identified as being important in predicting physician intention 
to recommend HPV vaccines. 
The outcome or dependant variables selected for inclusion in the final survey tool pertained 
to recommending and administering the HPV vaccine. The first outcome variable was HPV 
vaccine recommendation to 9-10 year olds, 11-12 year olds, 13-17 year olds, and 18-26 year 
olds. The second outcome variable is likelihood of recommending the HPV vaccine to 11-12 
year old boys and the third outcome variable was agreement with mandated ACIP guidelines of 
vaccinating 11-12 year old girls.  
The final survey tool developed for this research included 23 questions that were Yes/No, 
True/False, and Likert-type responses (Appendix D). The final survey question was open ended.  
This question allowed respondents the opportunity to share any information or valuable lessons 
learned about adopting a new vaccine into their practice.  Participants were asked to identify 
responses that best match with their perceived knowledge, barriers, practices, and adherence to 
the ACIP guidelines and recommendations. All questions pertained to the quadrivalent HPV 
vaccine Gardasil® and did not include questions on other vaccines.  This decision was made 
because Gardasil® is the only vaccine allowed under the VFC program at this time.  
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The first section of the survey tool accessed physician HPV knowledge, valued sources of 
information about HPV vaccines, educational needs related to HPV vaccines, barriers to HPV 
vaccination, frequency of HPV vaccine recommendation and administration to girls in four age 
groups (9-10, 11-12, 13-17, and 18-26 years) and intention to recommend the HPV vaccine to 
boys in the same four age groups.  
Physician knowledge about the HPV vaccine was measured with the use of seven items.  
These were: assessing HPV medical intervention, treatment of HPV, causes of genital warts and 
cervical cancer, FDA approval, and if a previous diagnosis of HPV precluded immunization.  
Physician and parental barriers to HPV vaccination were assessed through 12 Likert-type scale 
items.  
Practice characteristics included whether the physician cared for women in different age 
groups, patient demographic characteristics, patients’ insurance coverage, primary physician 
specialty, type of practice (Pediatric, Family Medicine, Internal Medicine, 
Obstetrics/Gynecology, Academic or other),and practice location (urban or rural).  Two 
questions explored physician vaccination adoption style.   
The remaining section of the survey contained demographic questions on the physician’s 
age, gender, and ethnicity.  All questions were quantitative in nature except the final question 
which was open-ended.  This question allowed respondents the opportunity to share any 
information or valuable lessons learned about adopting a new vaccine into their practice.  The 
qualitative data did not receive in-depth analysis, but was used to enhance findings and to be of 
use to others who wish to offer a new vaccine or increase their rates of immunization.  The 
variables included in this research are described in Table 2.  
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Table 2:   
Study Variables Description and Variable Type - HPV 
VARIABLE DESCRIPTION VARIABLE TYPE 
Administration of HPV 
vaccine to girls 
Intramuscular injection of the HPV vaccine to a 
female between the ages of 9 and 26 years 
Outcome Variable 
 
Recommendation of HPV 
vaccine to boys 
 
Recommending the HPV vaccine to male 
patients between the ages of 11 and 12 years. 
 
Outcome Variable 
 
Administration of HPV 
vaccine according ACIP 
guidelines 
 
 
Intramuscular injection of HPV vaccine to 
female between the ages of 11 and 12 years 
 
Outcome Variable 
Georgia County – Urban 
 
County with > or = 35,000 population Independent Variable 
Georgia County – Rural 
 
County with < 35,000 population Independent Variable 
Sources of Information Professional Organization 
ACIP guidelines 
State and local immunization programs 
Colleagues 
Pharmaceutical representatives 
Internet websites 
Media 
Medial conference 
Grand rounds 
Local   institutional lectures 
Independent Variables 
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Table 2.   
(Continued) Study Variables Description and Variable Type - HPV 
VARIABLE DESCRIPTION VARIABLE TYPE 
Barriers to HPV 
vaccination 
• Vaccine safety to the patient 
• Vaccine efficacy against HPV 
• Discussing sexuality/sexually transmitted   
infections with child or parent by physician 
• Administering a new vaccine with  limited  
track record of safety  
• Adding another vaccine to vaccine 
schedule 
• Lack of information about  the      
Quadrivalent HPV vaccine by child or 
parent  
• Cost of purchasing the vaccine (upfront 
cost to physician) 
• Cost of stocking HPV vaccine to the 
physician 
• Lack of adequate reimbursement for HPV 
vaccine to physician 
• Failure of some insurance companies to 
cover  the cost of HPV vaccine  
• Time to discuss HPV vaccination with 
patients and/or parents by physician 
• Difficulty ensuring patient will complete 
the 3 dose HPV vaccination series 
• HPV vaccination is not required for school  
attendance in Georgia 
Independent  Variable 
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Table 2.   
(Continued) Study Variables Description and Variable Type - HPV 
VARIABLE  DESCRIPTION VARIABLE TYPE 
Knowledge about HPV  
• Physician knowledge that  most HPV 
infections resolve without medical 
intervention 
• Physician knowledge that  HPV is a 
relatively common sexually transmitted 
infection 
• Physician knowledge that  HPV causes 
genital  warts in males and females 
• Physician knowledge that  almost all 
cervical cancers are caused by HPV 
infection 
• Physician knowledge that FDA approved 
the quadrivalent HPV vaccine for use in 
females ages 9-26 
• Physician knowledge that  females who 
have been diagnosed with an HPV 
infection may still receive the vaccine 
• Physician knowledge that  the FDA 
approved the quadrivalent HPV vaccine for 
use in  males for permissive use for ages 9-
26 
Independent Variable 
Clinic specialty 
 
Categorical variable of 
• Pediatrics 
• Family Medicine 
• Internal Medicine 
• Obstetrics/Gynecology 
• Academic  
•  Other 
Independent Categorical 
Variable  
Practice characteristics Categorical variable of 
• Single Specialty 
•  Multispecialty  
•  Other 
Independent Categorical 
Variable 
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Table 2.   
(Continued) Study Variables Description and Variable Type - HPV 
VARIABLE DESCRIPTION VARIABLE TYPE 
Number of physicians in 
practice 
Categorical variable of 
• 1 
• 2-5 
• 6-9 
• 10-14 
• 15-25 
• > 25 
Independent Categorical  Variable 
 
Race/Ethnicity of 
physician 
 
Categorical variable of 
• White/Caucasian 
•  Asian 
• Native Hawaiian/Pacific Islander 
• Black/African-American, American  
• Indian/Alaska Native 
• Mixed Race 
• Other, 
Independent Categorical Variable 
 
Years in practice since 
Residency 
 
Categorical variable classifying number of years 
since medical residency training 
 
Independent Categorical Variable 
 
Type of insurance 
 
Categorical variable of  
• Private insurance 
•  Medicaid, 
• PeachCare (state insurance for  low 
income children) 
• Uninsured/Self pay 
• Medicare 
• Other 
 
Independent  
Categorical Variable 
 
Age of Physician 
 
Categorical variable of the physician’s age at the 
time of survey 
 
Independent Categorical Variable 
 
Gender of Physician 
 
Categorical variable of  
• Male  
• Female 
 
Independent Categorical Variable 
 
Collection and Treatment of Data 
Data collection occurred between December 2010 and February 2011. Three steps were used 
to collect data (Table 3).  In step one, key informants such as physicians, immunization nurses or 
office managers at each physician location were identified to determine the size of the practice 
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and who would complete the survey. At this stage, an electronic format for respondents (i.e., 
Survey Monkey) was created and uploaded onto a dedicated webpage.   In step two, the 
physician or key informant who would respond to the survey for the physician was contacted to 
obtain his/her agreement to participate in the study.  This was to inform participants about the 
internet survey site and to verify that all contact information (i.e., electronic/postal mail 
addresses and phone numbers) was correct.  The third step involved second, third, and fourth 
survey mailing, postal mailing and follow-up phone calls (Appendices E, F, G, and H). An offer 
to complete a telephone survey with non-responders to maximize response rate was initiated 
during the month of January and occurred after the third phone call (Appendix I). Phone calls 
continued until all participants responded, or until the scheduled date for survey completion 
arrived – February 7, 2011. 
Table 3: 
  Survey Timetable 
Date Activity 
August/September 2010 Key information on Georgia physicians participating in VFC program 
identified 
 
October  20 – 30, 2010 
 
Survey Monkey format created for key informant survey 
  
November  1, 2010 
 
Survey posted to internet link 
 
November 8, 2010 
 
Phone calls and mail to physician responders  begins 
 
January 3 – January 31  2011 
 
Follow-up phone calls and mail to non-responders 
 
Week of February 7, 2011 
 
Deadline for survey completion 
 
Week of February 14, 2011 
 
Data entry begins 
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Analysis and Interpretation of the Data 
A survey instrument was administered to a sample of Georgia physicians in 14 public health 
districts in six urban and 18 rural counties.  The survey was sent to the sample of 264 providers.  
Respondents were asked about their knowledge of the vaccine and if they administered the 
vaccine according to ACIP guidelines by offering it to females at 11-12 years of age and if they 
recommend it to males according to ACIP guidelines of “permissive use.”  Respondents were 
also asked to respond to barriers they perceived to be associated with this vaccine.   
A final qualitative question was open-ended and allowed respondents to comment on their 
experience with the vaccine.  Prevalence data were created for all dependent measures to 
determine the percentage of perceived knowledge, barriers, practices, and adherence to ACIP 
guidelines where appropriate.  The qualitative data did not receive an in-depth analysis, but were 
used to augment findings and to record what may be useful to other providers and others who 
wish to offer a new vaccine or increase rates of immunization.  
Quantitative data analysis was performed using SAS.  Data came from a complex 
probability sample, and was summarized and analyzed using the SAS procedures, SurveyFreq, 
SurveyMeans, SurveyReg and SurveyLogistic.  SAS procedure SurveySelect was used to help 
select the sample using a PPS without replacement design.  As the data were the result of a 
complex probability based survey, results for strata and domains were generally presented in 
terms of confidence intervals which provide the most meaningful analysis.  A logistic regression 
analysis was performed to determine what may influence a physician’s decision to not 
recommend (dependent variable) HPV vaccine while payer type, physician barriers, and parental 
barriers served as the independent variables.  
   
49 
 
 
CHAPTER 4 
RESULTS 
The purpose of this study was to examine the prevalence of Georgia physician intention and 
administration of the HPV vaccine to 11-12 year-old girls and intention to recommend the HPV 
vaccine to 11-12 year old boys.  The study accessed perceived knowledge, barriers, practices, 
and adherence to ACIP guidelines and recommendations regarding HPV vaccination.  The 
Health Belief Model (Champion & Skinner, 2008; Glantz, et al., 2008) was used to guide this 
study of Georgia physicians.   
This chapter is organized into the following sections to present study results: (1) sample 
characteristics; (2) descriptive analysis of survey questions; (3) descriptive analysis for variables; 
(4) analysis of the research questions and hypotheses and analysis of variables associated with 
not recommending the HPV vaccine. 
Sample Characteristics 
A stratified single stage 100% cluster sample with counties being the cluster was performed.  
Two strata were formed, urban and rural.  Sampling weights for the clusters were computed 
based on the number of providers within the county.  The number of providers within a county 
divided by the number of providers in the state was the probability of a county being selected.  
The sampling weight is the inverse of the probability of selection.  Once a cluster was selected 
then all providers within that county were included in the survey (hence 100% cluster sample).  
All computations were performed using SAS Proc SurveyMeans, Proc SurveyFreq and Proc 
SurveyLogistic. 
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The initial sampling frame included 389 (N = 389) provider locations.  Of these, 305 were 
located in six urban counties and 84 were in18 rural counties. Of the 389 physicians, 264 
(67.9%) responded to telephone contact and stated they administered the HPV vaccine, 95 
(24.4%) stated they did not administer the HPV vaccine and 30 (7.7%) were unable to be 
contacted by telephone or postal mail.   
Of the 264 who administered the HPV vaccine, 62 (23.5%) were in 18 rural counties located 
in ten public health districts and 202 (76.5%) were in six urban counties located in ten public 
health districts.  These 264 providers served as the study’s population for HPV survey 
administration (n=264). 
There were 42 physician locations (17.4%) that did not respond to the request to take part in 
the survey.  Thirty eight (14.4%) of the 42 stated their refusal to participate when contacted and 
the remaining eight (3%) could not be contacted by telephone or postal mail.  There were 218 
physicians or key informants who could represent the physician in the Georgia study population 
who positively responded to the survey questionnaire yielding a response rate of 82.6%.  Of the 
218 respondents, 15 (6.8%) responded through Survey Monkey, 72 (33%) responded though the 
postal mail and 131 (60.1%) responded by telephone survey.  Table 4 displays the method by 
which the 214 physicians responded to the survey questionnaire. 
Table 4:  
 Method by Which Physicians Responded to Survey 
Variable n Percent 
          Survey Monkey 
     Postal Mail survey  
     Telephone survey 
 
Responded to survey 
15 
72 
131 
 
218 
5.7 
33 
60.1 
 
100 
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Demographic variables of the respondents were obtained; however, not all respondents 
answered all questions in the survey.  The variables of race, ethnicity, gender, and years in 
practice were included in the survey.  Respondents were predominantly white (109 or 51.4%) 
followed by Asian respondents (48 or 22.6%) followed by African American (39 or 18.4%).  
There were 10 (7.3%) who preferred not to answer and seven (3.3%) who listed their race as 
other.  Six of the 218 did not respond to this question. 
Most respondents (190 or 90.5%) self identified as non Hispanic or Latino. Two hundred ten 
(96.3%) responded to the question of gender with slightly more male’s (107 or 51%) than 
female’s (103 or 49%).   Forty four physicians (25%) had been in practice 0-9 years, followed by 
65 (36.9%) in practice from 10-19 years. Forty-one physicians (23.3%) had been in practice 20 – 
29 years and 26 (18.8%) had been in practice for 30 years or more.  Table 5 displays the 
demographic characteristics. 
Table 5:   
Physician Demographic Characteristics 
Variable n Percent 
Race 
     White 
     Asian 
     Black or African American 
     Prefer not to answer 
     Other 
      
Responded to question (one responded in two categories) 
 
109 
48 
39 
10 
7 
 
212 
 
51.4 
22.6 
18.4 
4.7 
3.3 
 
100% 
Hispanic/Latino 
    Identified as Hispanic or Latino 
    Did not identify as Hispanic or Latino 
 
Responded to question 
 
20 
190 
 
210 
 
9.5 
90.5 
 
100% 
Years in Practice 
    0-9 years 
   10-19 years 
    20-29 years 
 
44 
65 
41 
 
25 
36.9 
23.3 
   
52 
 
Variable n Percent 
    >30 years 
 
Responded to question 
26 
 
176 
18.8 
 
100% 
Physician Gender 
    Male 
    Female 
 
Responded to question 
 
107 
103 
 
210 
 
51% 
49% 
 
100% 
 
Information on physician practice variables was obtained.   The majority of respondents 
(182 or 85%) were in a single practice specialty, followed by 27 (12.7%) in multi-specialty 
practices.  Three (1.4%) respondents listed other for practice characteristics.  These were 
Federally Qualified Health Clinics or medical clinics associated with a teaching hospital with 
physician oversight.   
Two hundred thirteen responded to the question on primary clinical practice specialty. Sixty 
eight (31.9%) identified their specialty as Family Medicine, seven (3.3%) identified as Internal 
Medicine, and seven (3.3%) identified as Obstetricians/Gynecologists. The majority (126 or 
59%) identified as pediatricians.  Approximately 2.3% self identified as other.   
Most physicians (102 or 47.9%) were in a solo practice, meaning they were the only 
physician in their respective practices. Ninety-two (43.2%) were in practice with as many as four 
other physicians.  Ten (4.7%) respondents practiced with six to nine other physicians.  Five 
(1.4%) were in practice with as many as 25 other physicians and one practice (0.5%) reported 
over 26 physicians.  For the purposes of this research, resident physicians, nurse practitioners 
and physician assistants working with the physician were excluded.  
Reimbursement in various forms was accepted by most physicians.  Of the 206 who 
responded to this question, private insurance and Medicaid was accepted by all physicians at 
practice locations.  The Georgia Children’s Health Insurance or PeachCare was accepted by 202 
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physicians (98%).  Uninsured or patients paying for services themselves were accepted by 204 
physicians (99%) and Medicare was accepted by 195 physicians (94.6%).  Other forms of 
payment (such as military reimbursement) were accepted by 81.5% of physicians. 
Urban or rural classification was coded by the researcher after all surveys were submitted.  
Using the definition from by the Georgia Office of Rural Health (2002), 176 physicians (80.7%) 
practiced in an urban county and 42 (19.3%) practiced in a rural county.  If the physician or key 
informant completing the survey questionnaire for the physician had a practice in more than one 
location, the respondent was asked to complete the survey by answering questions as if it 
pertained only to that practice location.  For example, if the physician gave HPV vaccine to 
males at one location but did not administer the vaccine at the location that received the survey, 
the physician or key informant was asked to answer survey questions at it pertained to the 
location that received the survey.  Table 6 displays demographic variables of the physician’s 
practice. 
Table 6:   
Physician Practice Demographic Characteristics 
Variable n Percent 
Practice Characteristics 
    Single specialty 
    Multi specialty 
    Other 
 
Responded to question 
 
182 
27 
3 
 
212 
 
85.8 
12.7 
1.4 
 
100% 
 Practice Classification 
     Family Medicine 
     Internal Medicine 
     Obstetrics/Gynecology 
     Pediatrics 
     Other 
 
Responded to question      
 
68 
7 
7 
126 
5 
 
213 
 
31.9 
3.3 
3.3 
59.2 
2.3 
 
100 
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Variable n Percent 
Physicians at Location 
     1 
     2-5 
     6-9 
     10-14    
     15-25 
     > 26 
 
Responded to question 
 
102 
92 
10 
3 
5 
1 
 
213 
 
47.9 
43.2 
4.7 
1.4 
2.3 
0.5 
 
100 
   
Reimbursement  Accepted by Practice 
     Private insurance 
     Medicaid 
     PeachCare of Georgia 
     Uninsured/Self-pay 
     Medicare 
     Other (example: Military) 
 
Responded to question 
 
206 
206 
202 
204 
195 
168 
 
206 
 
100 
100 
98 
99 
94.6 
81.5 
 
100 
County classification 
     Urban 
     Rural 
 
Coded by researcher 
 
176 
42 
 
218 
 
80.7 
19.3 
 
100% 
 
Descriptive Analysis of Survey Questions 
Nine items assessing valued sources of information about HPV vaccine are shown in Table 
7.  Most of the 215 respondents (94.4%) indicated professional organization was a source of 
information on HPV vaccine.  The ACIP as a source was reported by 92.1%).  State and local 
immunization programs were noted by 197 respondents (92.5%) and information from the HPV 
pharmaceutical representatives (92.5%) was a reported source of HPV information.  Going to 
colleagues (86.4%), internet websites (81.5%), and medical conferences (77.9%) were not as 
valued. Least valued were media sources (44.1%) and grand rounds or location institution 
lectures (27.2%) by respondents. 
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Table 7:   
Sources of Information 
Variable n Percent 
Valuable sources of information about HPV vaccination 
     Professional Organizations (e.g., AAFP, ACOG, AAP, SGIM) 
     Advisory Council of Immunization Practice (ACIP) 
     State and local immunization programs 
     Colleagues 
     Pharmaceutical representative 
     Internet websites 
     Media 
     Medical conferences 
     Grand rounds/local institutional lectures 
 
Responded to question 
 
203 
198 
197 
184 
197 
174 
94 
166 
58 
 
215 
 
94.4 
92.1 
92.5 
86.4 
92.5 
81.5 
44.1 
77.9 
27.2 
 
100% 
 
Seven items assessing knowledge about HPV vaccine were determined.  Of the 214 
respondents, 164 (76.7%) knew HPV infections resolved without medical intervention, 184 
(86.4%) knew HPV was a common sexually transmitted disease, and 192 (90.6%) knew HPV 
caused genital warts in males and females. The FDA approval of the vaccine for use in females 
ages 9-26 was known by 208 (97.2%) while 169 (79.3%) knew that a previous HPV infection did 
not preclude a female from being vaccinated.  Lastly, the FDA approval of the vaccine for males 
for permissive use for ages 9-26 years was known by 200 (94.8%) of the respondents.  The seven 
items assessing knowledge about HPV vaccine are shown in Table 8.  
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Table 8:   
Knowledge About HPV 
Variable n Percent 
Knowledge items (correct) 
    Most HPV infections resolve without medical interventions 
    HPV is a relatively common sexually transmitted disease 
    HPV causes genital warts in males and females 
    Almost all cervical cancers are caused by HPV infection 
    The FDA approved the quadrivalent HPV vaccine for use in  
         females ages 9-26 
    Females diagnosed with HPV infection can be given the vaccine 
    The FDA approved the quadrivalent HPV vaccine for use in  
         males ages 9-26 
 
Responded to question 
 
164 
184 
192 
195 
208 
 
169 
200 
 
 
214 
 
76.7 
86.4 
90.6 
91.1 
97.2 
 
79.3 
94.8 
 
 
100% 
 
Barriers to vaccination attributed to the physician were assessed through 12 items. The 
responses of sometimes, often and always were summed to achieve the number of physicians 
who perceived these as barriers to administering the HPV vaccine. A total of 212 responded as 
illustrated in Table 9.  Of those who responded, 21 (9.9%) were concerned about vaccine safety 
and 22 (10.3%) were concerned about the efficacy of the HPV vaccine.  Administering a new 
vaccine with a limited track record of safety was a barrier to 32 physicians (15.1%) and 22 
physicians (10.3%) believed adding another vaccine to the vaccine schedule was a barrier.  Lack 
of information about the vaccine was perceived as a barrier by 12.7% of the respondents. 
The initial cost, or upfront cost of purchasing the vaccine was considered a barrier among 
129 respondents (60.8%) and 134 respondents (63.2%) believed cost of stocking the vaccine to 
be a barrier to their practice.  Lack of adequate reimbursement for the vaccine was considered a 
barrier among 136 respondents (64.2%) and failure of some insurance companies to cover the 
cost of vaccination was a barrier among 126 respondents (59.4%).  Only 40 respondents (18.7%) 
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considered the time it takes to discuss the vaccine with parents or patients to be a barrier.  
Moreover 90 respondents (42.5%) believed that ensuring the completion of the 3-dose series to 
be a barrier.  HPV vaccination not being a requirement for school attendance was perceived to be 
a barrier among 15.1% of those responding.   
Table 9:   
Barriers to HPV Vaccination – Physician 
Variable  n Percent 
Barriers related to immunizing against HPV 
     Concerns about vaccine safety 
     Concerns about vaccine efficacy 
     Administering a new vaccine with a limited track record of safety 
     Adding another vaccine to the vaccine schedule 
     Lack of information about the vaccine 
     Up front cost of purchasing  private stock vaccine 
     Cost of stocking the vaccine 
     Lack of adequate reimbursement for the vaccine 
     Failure of some insurance companies to reimburse the vaccine 
     Time to discuss the vaccine with parents and/or patients 
     Difficulty ensuring 3-dose vaccine compliance 
     Vaccine is not required for school attendance 
 
Responded to the question 
 
21 
22 
32 
22 
27 
129 
134 
136 
126 
40 
90 
34 
 
212 
 
9.9 
10.3 
15.1 
10.3 
12.7 
60.8 
63.2 
64.2 
59.4 
18.7 
42.5 
15.1 
 
100 
 
Twelve barriers to vaccination attributed to the parent were assessed. The responses of 
sometimes, often, and always were summed to achieve the number of physicians who perceived 
these to be barriers recognized by the parent as not allowing the male or female child to be 
vaccinated.  A total of 208 physicians, or key informants, who responded as the physician, 
completed this section.   Of those who responded, 137 (65%) believed the parent had concerns 
about vaccine safety and 78 respondents (37.5%) believed the parent had concerns about vaccine 
efficacy.  A larger group (77.9%) believed parents were reluctant to discuss sexuality or sexually 
transmitted infections, while 145 respondents (69.7%) indicated parental concerns that their child 
would assume approval of premarital sex if the parent agreed to vaccination.  Lack of parental 
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education or understanding about the vaccine was given by 173 respondents (84.3%) and 168 
respondents (80.8%) believed the parent thought their child was not at risk for HPV infection.  
Parental consent to vaccination was not considered a significant barrier and was given by 121 
respondents (58.2%). Parent opposition to HPV vaccination for moral or religious reasons 
appeared to be the least important barrier as indicated by 53 respondents (25.5%).   Physicians 
who believed parents thought their child was too young for vaccination numbered 168 (80.8%) 
and parental concern about negative media reports related to the HPV vaccine was low (40.4%). 
Table 10 displays parental barrier variables to HPV vaccine. 
Table 10:   
Barriers to HPV Vaccination - Parental 
Variable n Percent 
Barriers related to immunizing against HPV 
     Concerns about vaccine safety 
     Concerns about vaccine efficacy 
     Reluctance to discuss sexuality/sexually transmitted infections 
     Concern adolescent will assume that parent who agrees to  
           vaccination condones premarital sex 
     Concern vaccinated child will practice riskier sexual behaviors 
     Lack of education/understanding of HPV infection 
     Request that vaccination be deferred 
     Belief that adolescent is not a risk for HPV infection 
     Will not consent to vaccination 
     Opposition to vaccination for moral or religious reasons 
     Belief that adolescent is too young for vaccination 
     Concern about negative media reports related to vaccine 
 
Responded to the question 
 
137 
78 
162 
145 
 
144 
173 
187 
168 
121 
53 
168 
84 
 
208 
 
65 
37.5 
77.9 
69.7 
 
69.2 
83.2 
89.9 
80.8 
58.2 
25.5 
80.8 
40.4 
 
100 
 
 
Respondents were asked if they recommended the HPV vaccine, as well as the patient’s age 
when the recommendation was made.  Responses are profiled in Table 11.  Of the 209 who 
responded for 9-10 year old females, 58 (27.8%) reported they never offer the vaccine at this 
age, 57 (27.3%) offered it rarely and 30 (14.4%) indicated they sometimes offered the vaccine.   
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Twenty-three (11.0%) reported they offered the vaccine often and 34 (16.3%) reported they 
always offered the HPV vaccine to female patients in this age group. Seven (3.3%) responded 
they did not see patients in this age group.   
Of the 210 who responded regarding their 11-12 year old female patients, 10 (4.8%) 
reported they never offer the vaccine at this age, 30 respondents (14.3%) offered it rarely and 19 
respondents (9.0%) sometimes offered the vaccine.  Forty respondents (19.0%) reported they 
offered the vaccine often and 106 (50.5%) reported they always offered the HPV vaccine to 
female patients in this age group.  Five respondents (2.4%) indicated they did not see patients in 
this age group.   
Of the 209 who responded regarding their 13-17 year old females, none (0%) reported they 
never offer the vaccine at this age indicating they offer the vaccine to females at this age.  Only 2 
(1%) did so rarely and 17 (8.1%) responded they sometimes offered the vaccine.  Forty-four 
respondents (21.1%) reported they offered the vaccine often and 50.5% of respondents reported 
they always offered the HPV vaccine to female patients in this age group.  Five (2.4%) 
responded they did not see patients in this age group.   
Of the 207 who responded for 18-26 year old females, none (0%) reported they never offer 
the vaccine indicating they offer to all females at this age.  Only 4 (1.9%) did so rarely and 15 
(7.2%) responded they offered the vaccine sometimes.  Thirty-three (15.9%) reported they 
offered the vaccine often and 53.6% physicians reported they always offered the HPV vaccine to 
female patients in this age group.  Forty-four (21.3%) responded they did not see patients in this 
age group.  
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Table 11:   
Recommend HPV Vaccine to Girls by Age Group 
 
 9-10 y 
--------- 
n (%) 
11-12 y 
--------- 
n  (%) 
13-17 y 
--------- 
n  (%) 
18-26 y 
--------- 
n  (%) 
Never   (never recommend) 58  (27.8) 10  (4.8) 0 (0.0) 0  (0.0) 
Rarely   (recommend 1-25%) 57  (27.3) 30  (14.3) 2 (1.0) 4  (1.9) 
Sometimes (recommend 26-50%) 30  (14.4) 19  (9.0) 17  (8.1) 15  (7.2) 
Often  (recommend 51-75%) 23  (11.0) 40  (19.0) 44  (21.1) 33  (15.9) 
Always  (recommend >76%)  34  (16.3) 106  (50.5) 146 (69.9) 111  (53.6) 
Do not see patients in this age group 7  (3.3) 5  (2.4) 0  (0.0) 44  (21.3) 
 
Responded to question 
 
209 
 
210 
 
209 
 
207 
 
Respondents were then asked at what age they administered at least one dose of HPV 
vaccine to their female patients. Responses to this question are illustrated in Table 12.  Of the 
210 who responded for 9-10 year old females, 79 (37.6%) reported they never administer the 
vaccine at this age, approximately one-third (33.8%) did so only rarely and 31 (14.8%) 
responded they offered the vaccine sometimes. Sixteen (7.6%) reported they offered the vaccine 
often and 34 (16.3%) reported they always administered the HPV vaccine to female patients in 
this age group. Seven (3.3%) responded they did not see patients in this age group.   
Of the 209 who responded for 11-12 year old females, 17 (8.1%) reported they never 
administered the vaccine to female patients at this age, 48 respondents (23%) did so only rarely 
and 51 respondents (24.4%) indicated they administered the vaccine sometimes. Approximately 
one-third (30.1%) reported they administered the vaccine often and 25 respondents (12%) 
indicated they always administered the HPV vaccine to female patients in this age group. Five 
respondents (2.4%) indicated they did not see patients in this age group.   
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Of the 210 who responded for 13-17 year old females, none (0%) reported they never 
administered the vaccine at this age indicating all respondents administer to females at this age.  
Although 10 respondents (4.8%) indicated they offered it rarely and approximately one-third 
(31.9%) responded they administered the vaccine sometimes. Eighty-five (40.5%) reported they 
administered the vaccine often and 106 (50.5%) reported they always administered the HPV 
vaccine to female patients in this age group. Five (2.4%) responded they did not see patients in 
this age group.   
Of the 208 who responded for 18-26 year old females, none of the physicians (0%) reported 
they never administered the vaccine indicating all administer the vaccine to all females at this 
age.  Fourteen (6.7%) did so rarely and approximately one-fourth (24%) responded they offered 
the vaccine sometimes.  Approximately one-third (32.7%) reported they offered the vaccine 
often and 34 physicians (16.3%) reported they always offered the HPV vaccine to female 
patients in this age group. Forty-two (20.2%) responded they did not see patients in this age 
group.  
Table 12:   
Administer HPV to Girls by Age Group 
 
 9-10 y 
--------- 
n  (%) 
11-12 y 
--------- 
n  (%) 
13-17 y 
--------- 
n  (%) 
18-26 y 
--------- 
n  (%) 
Never   (never administered) 79  (37.6) 17  (8.1) 0  (0.0) 0  (0.0) 
Rarely   (administered 1-25%) 71  (33.8) 48 (23.0) 10  (4.8) 14  (6.7) 
Sometimes (administered 26-50%) 31  (14.8) 51  (24.4) 67  (31.9) 50  (24.0) 
Often  (administered 51-75%) 16  (7.6) 63  (30.1) 85  (40.5) 68  (32.7) 
Always  (administered >76%)  6  (2.9) 25  (12.0) 48  (22.9) 34  (16.3) 
Do not see patients in this age group 7  (3.3) 5  (2.4) 0 (0.0) 42  (20.2) 
 
Responded to question 
 
210 
 
209 
 
210 
 
208 
 
   
62 
 
Parental refusal to allow their daughters to be vaccinated is a barrier. Respondents were then 
asked if parents refused to allow their daughters to be vaccinated when the physician offered or 
recommended the HPV vaccine, and at what age did refusal occur.  Responses are illustrated in 
Table 13.  Of the 202 who responded for 9-10 year old females, seven physicians (3.5%) 
reported they never experienced a parent who refused to have their daughter vaccinated with the 
HPV vaccine once it was offered.  Twelve (5.9%) indicated this occurred only rarely and 41 
(20.3%) responded this sometimes.  Over one-fourth (25.7%) reported they experienced this 
often and 83 (41.1%) reported they always experienced refusal with this age group.  Seven 
(3.3%) responded they did not see patients in this age group.   
Of the 205 who responded for 11-12 year old females, three physicians (1.5%) reported they 
never experienced a parent who refused to have their daughter vaccinated with the HPV vaccine 
once it was offered.  Thirty-eight (18.5%) indicated this occurred only rarely and 88 (42.9%) 
responded this occurred sometimes.  Over one-fourth (25.4%) reported they experienced this 
often and only 19 physicians (9.3%) reported they always experienced refusal with this age 
group.  Five (2.4%) responded they did not see patients in this age group.  Of the 208 who 
responded for 13-17 year old females, seven physicians (3.4%) reported they never experienced 
a parent who refused to have their daughter vaccinated with the HPV vaccine once it was 
offered.  Approximately one-third (34.1%) indicated vaccine refusal occurred only rarely and 
over half (55.8%) responded this occurred sometimes.  Twelve respondents (5.8%) reported they 
experienced vaccine refusal occurred often and few (1.0%) reported they always experienced 
refusal with this age group.   
Of the 207 who responded for 18-26 year old females, eight physicians (3.9%) reported they 
never experienced a parent who refused to have their daughter vaccinated with the HPV vaccine 
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once it was offered.  Approximately one-third (30%) indicated this occurred only rarely and 86 
(41.5%) responded this occurred sometimes.  Seven (3.4%) reported they experienced this often 
and few (1.0%) reported they always experienced refusal with this age group.  Forty-two 
physicians (20.3%) did not see female patients in this age group. 
Table 13:   
Parental Refusal of HPV Vaccine to Girls by Age Group 
 9-10 y 
--------- 
n (%) 
11-12 y 
--------- 
n (%) 
13-17 y 
--------- 
n (%) 
18-26 y 
--------- 
n (%) 
Never   (never refused) 7  (3.5) 3  (1.5) 0  (0.0) 0  (0.0) 
Rarely   (refused 1-25%) 12  (5.9) 38 (18.5) 10  (4.8) 14  (6.7) 
Sometimes   (refused 26-50%) 41  (20.3) 88  (42.9) 67  (31.9) 50  (24.0) 
Often   (refused 51-75%) 52  (25.7) 52  (25.4) 85  (40.5) 68  (32.7) 
Always   (refused >76%)  83  (41.1) 19  (9.3) 48  (22.9) 34  (16.3) 
Do not see patients in this age group 7  (3.5) 5  (2.4) 0 (0.0) 42  (20.2) 
 
Responded to question 
 
202 
 
205 
 
208 
 
207 
 
The ACIP recommends optional HPV vaccination for males to protect them from genital 
warts, although the ACIP stopped short of recommending routine use in males.  Of the 211 who 
responded for 9-10 year old males, 86 physicians (40.8%) reported they never recommend their 
male patients receive the HPV vaccine.  Forty-nine (23.2%) did so only rarely and 23 (10.9%) 
responded they offered the vaccine sometimes. Twenty-two (10.4%) reported they offered the 
vaccine often and 23 (10.9%) reported they always offered the HPV vaccine to male patients in 
this age group. Eight (3.4%) responded they did not see patients in this age group.   
Of the 211 who responded regarding their 11-12 year old male patients, 49 respondents 
(23.2%) reported they never offer the vaccine at this age, 34 respondents (16.1%) did so only 
rarely and 29 respondents (13.7%) indicated they offered the vaccine sometimes. Forty-one 
(19.4%) reported they offered the vaccine often and 50 (23.7%) reported they always offered the 
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HPV vaccine to male patients in this age group. Eight (3.8%) responded they did not see patients 
in this age group.   
Of the 208 who responded regarding their 13-17 year old males, 37 (17.8%) reported they 
never offer the vaccine at this age.  Thirty-two (15.4%) did so rarely and 34 (16.3%) responded 
they offered the vaccine sometimes. Forty-two (20.2%) reported they offered the vaccine often 
and slightly over one-fourth (26.9%) reported they always offered the HPV vaccine to male 
patients in this age group. Seven (3.4%) responded they did not see patients in this age group.   
Of the 210 who responded for 18-26 year old males, 29 physicians (13.8%) reported they 
never offer the vaccine to all males at this age.  Thirty-three physicians (15.7%) did so rarely and 
25 (11.9%) responded they offered the vaccine sometimes. Thirty (14.3%) reported they offered 
the vaccine often and 47 physicians (22.4%) reported they always offered the HPV vaccine to 
male patients in this age group. Forty-six (21.9%) responded they did not see patients in this age 
group.  Responses are profiled in Table 14.   
Table 14:   
Recommend HPV Vaccine to Boys by Age Group 
 9-10 y 
--------- 
n (%) 
11-12 y 
--------- 
n (%) 
13-17 y 
--------- 
n (%) 
18-26 y 
--------- 
n (%) 
Never   (never recommend) 86  (40.8) 49  (23.2) 37  (17.8) 29  (13.8) 
Rarely   (recommend 1-25%) 49  (23.2) 34  (16.1) 32  (15.4) 33  (15.7) 
Sometimes (recommend 26-50%) 23  (10.9) 29  (13.7) 34  (16.3) 25  (11.9) 
Often  (recommend 51-75%) 22  (10.4) 41  (19.4) 42  (20.2) 30  (14.3) 
Always  (recommend >76%)  23  (10.9) 50  (23.7) 56  (26.9) 47  (22.4) 
Do not see patients in this age group 8  (3.8) 8  (3.8) 7  (3.4) 46  (21.9) 
 
Responded to question 
 
211 
 
211 
 
208 
 
210 
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Analysis of Research Questions and Hypotheses 
Research Question #1 
What barriers do Georgia physicians enrolled in the Vaccine for Children (VFC) 
program perceive when providing the Human Papillomavirus Virus (HPV) vaccine to 
their female patients? 
 
For those physicians that responded, 64.2% believed the most important barrier for not 
vaccinating was lack of adequate reimbursement for HPV vaccination.  This was followed by 
63.2% citing the cost of stocking the HPV vaccine, 60.8% believed the upfront or initial cost of 
purchasing the private stock HPV vaccine, and 59.4% believed the failure of some insurance 
companies to cover the cost of the vaccine was a barrier.  Difficulty ensuring that patients will 
complete the 3-dose HPV vaccination series was cited as a barrier by 42.5% of respondents.  
Barriers dropped sharply with 18.7% indicating the time it takes to discuss HPV vaccination with 
patients and or parents as a barrier.  Administering a new vaccine with a limited track record of 
safety was a barrier to only 15.1% of respondents and lack of information was a barrier to 12.7% 
of respondents.  Adding another vaccine to the vaccine schedule and concerns about efficacy of 
the HPV vaccine was a barrier to 10.3% respectively.  Only 9.9% had concerns about the safety 
of the HPV vaccine. 
The most significant parental barrier to vaccination according to physicians was the request 
that HPV vaccine be deferred until the female patient was older.  This barrier was noted by 
89.9% of respondents followed by lack of education/understanding of the HPV vaccine (83.2%).  
Physicians noted parental belief that the daughter was too young and the barrier that they 
believed the daughter was not at risk for HPV infection were 80.8% respectively.  Reluctance to 
discuss sexuality or sexually transmitted infections by the parent was 77.9%.  This was followed 
   
66 
 
by 69.7% believing parental concern that the adolescent assumed parents who agree to HPV 
vaccination condone premarital sex.  Slightly more than two-thirds or 69.2% believed parent has 
concerns that the vaccinated adolescent would practice riskier sexual behaviors.  Parental 
concern about vaccine safety was noted by 65% of the respondents.  Refusal to consent to have 
the adolescent vaccinated was a barrier of 58.2% respondents.  Parental concerns about negative 
media reports related to the HPV vaccine was a barrier to only 40.4% and parental concern about 
vaccine efficacy was a concern to 37.5%.   
In summary, barriers to HPV vaccination for physicians focused on the cost of purchasing 
and storing the vaccine by the physician and lack of adequate reimbursement.  The physician 
time it takes to talk about or educate about the vaccine was viewed as less of a barrier.  The least 
mentioned barrier was parental opposition to HPV vaccination for moral or religious reasons.  
The most important barrier for parents toward HPV vaccination was the parental request that 
vaccination be deferred.  This barrier was followed by lack of education or understanding of the 
vaccine.  Many physicians cited as a common barrier the parents’ belief that their female child 
was not a risk for HPV infection.  
Research Question #5: 
 
What differences will emerge when the data are analyzed by urban vs. rural 
characteristics? 
 
To answer research question #5, Hypothesis #1 was tested. 
Hypothesis #1: 
 
No statistical differences will be detected between perceived barriers by physicians 
enrolled in the VFC program who provide the HPV vaccine to females and geographic 
setting (urban vs. rural).   
  
   
67 
 
Due to missing cells in the response categories, tests of hypothesis could not be performed, 
however estimates of proportions and their standard errors were calculated and no statistical 
significance was detected between perceived barriers by physicians enrolled in the VFC program 
that provide the HPV vaccine to females, and geographic setting.  Estimates of proportions and 
their standard errors to physician perceived barriers are listed in Table 15 and estimates of 
proportions and their standard error to parental barriers are listed in Table 16.  Since confidence 
intervals were overlapping across response categories between urban and rural practice setting, 
no statistical differences were detected 
Table 15:   
Responses to Question #3 
 Strongly 
Disagree 
Somewhat 
Disagree 
Neutral Somewhat 
Agree 
Strongly Agree 
Concern about 
vaccine safety 
Q3A  Rural 
 
.4 
(.317,  .484) 
 
.4 
(.316, .483) 
 
.18 
(.103, .257) 
 
.02 
(0, .053) 
 
0 
- 
Q3A  Urban 
 
.442 
(.326, .558) 
.255 
(.17, .341) 
.19 
(.096, .284) 
.109 
(.042, .176) 
.003 
(.0, .007) 
Concern about 
vaccine efficacy 
Q3B  Rural 
 
.381 
(.297, .464) 
 
.4 
(.33, .47) 
 
.18 
(.11, .25) 
 
.04 
(0, .087) 
 
0 
- 
Q3B  Urban 
 
.407 
(.292, .521) 
.289 
(.196, .381) 
.191 
(.098, .285) 
.109 
(.042, .177) 
.003 
(.0, .007) 
Administering a new 
vaccine with limited 
safety track record  
Q3C  Rural 
 
.262 
(.186, .337) 
 
.478 
(.396, .561) 
 
.18 
(.103, .257) 
 
.08 
(.014, .146) 
 
0 
- 
Q3C  Urban 
 
.162 
(.091, .233) 
.371 
(.264, .478) 
.291 
(.197, .384) 
.177 
(.09, .263) 
0 
- 
Adding another 
vaccine to schedule 
Q3D  Rural 
 
.302 
(.228, .375) 
 
.395 
(.325, .464) 
 
.244 
(.163, .324) 
 
.06 
(.013, .107) 
 
0 
- 
Q3D  Urban 
 
.188 
(.104, .272) 
.333 
(.227, .440) 
.347 
(247, .446) 
.117 
(.04, .195) 
.015 
(.002, .028) 
Lack of information 
about the vaccine 
Q3E  Rural 
 
.162 
(.085,  .239) 
 
.524 
(.44, .607) 
 
.264 
(.174, .354) 
 
.051 
(.001, .101) 
 
0 
- 
Q3E  Urban 298 .373 .175 .154 0 
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 Strongly 
Disagree 
Somewhat 
Disagree 
Neutral Somewhat 
Agree 
Strongly Agree 
(.193, .402) (.262, .484) (.11, .241) (.074, .234) - 
Upfront cost of 
purchasing vaccine 
Q3F  Rural 
 
0 
- 
 
.119 
(.072, .166) 
 
.319 
(.232, .406) 
 
.411 
(.325, .497) 
 
.151 
(.076, .226) 
Q3F  Urban .044 
(0, .091) 
.035 
(.018, .051) 
.18 
(.096, .263) 
.601 
(.492, .711) 
.14 
(.06, .221) 
Cost of stocking 
vaccine 
Q3G  Rural 
 
0 
- 
 
.099 
(.066, .132) 
 
.279 
(.201, .356) 
 
.471 
(.385, .557) 
 
.151 
(.071, .23) 
Q3G  Urban .046 
(0, .092) 
.036 
(.0175, .054) 
.13 
(.064, .196) 
.643 
(.543, .744) 
.145 
(.061, .23) 
Lack of 
reimbursement 
Q3H  Rural 
 
0 
- 
 
.105 
(.07, .14) 
 
.318 
(.228, .407) 
 
.306 
(.203, .409) 
 
.271 
(.17, .372) 
Q3H Urban 
 
 
.043 
(0, .089) 
.033 
(.002, .064) 
.167 
(.094, .241) 
.511 
(.395, .626) 
.246 
(.146, .347) 
Failure of some 
insurance to pay 
Q3I  Rural 
 
0 
- 
 
.163 
(.097, .228) 
 
.330 
(.251, .408) 
 
.336 
(253, .42) 
 
.171 
(.085, .257) 
Q3I  Urban .035 
(0, .080) 
.044 
(.011, .078) 
.217 
(.131, .304) 
.467 
(.354, 581) 
.236 
(.136, .336) 
Time it takes to talk 
about the vaccine  
Q3J  Rural 
 
0 
- 
 
.384 
(.297, .47) 
 
.426 
(.35, .501) 
 
.191 
(.108, .274) 
 
0 
- 
Q3J  Urban 
 
.036 
(.018, .054) 
.357 
(.245, .469) 
.448 
(.342, .553) 
.158 
(.078, .237) 
.002 
(0, .004) 
Difficulty ensuring 
patient completes 3-
dose series 
Q3K  Rural 
 
.020 
(0, .054) 
 
.174 
(.108, .24) 
 
.261 
(.183, .339) 
 
.524 
(.424, .624) 
 
.020 
(0, .054) 
Q3K Urban 
 
.072 
(.015, .130) 
.260 
(.154, .365) 
.258 
(.158, .358) 
.362 
(.253, .472) 
.048 
(0, .095) 
Not required for 
school attendance 
Q3L  Rural 
 
.060 
(.003, .117) 
 
.043 
(.347, .512) 
 
.202 
(.145, .258) 
 
.265 
(.188, .341) 
 
.044 
(0, .096) 
Q3L Urban 
 
.075 
(.019, .132) 
.205 
(.121, .288) 
.451 
(.342, .56) 
.201 
(.129, .273) 
.068 
(.007, .129) 
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Table 16:  
 Responses to Question #4 
 Never 
0% 
Rarely 
1-25% 
Sometimes 
26-29% 
Often 
51-75% 
Always 
>75% 
Concern about vaccine 
safety  
Q4A  Rural 
 
.011 
(0, .029) 
 
.359 
(.277, .442) 
 
.474 
(.386, .563) 
 
.135 
(.06, .209) 
 
.020 
(0, .054) 
Q4A  Urban .030 
(0, .081) 
.340 
(.228, .451) 
.537 
(.422, .652) 
.088 
(.049, .127) 
0 
- 
Concern about vaccine 
efficacy 
Q4B  Rural 
 
.052 
(.009, .094) 
 
.476 
(.386, .566) 
 
.400 
(.323, .477) 
 
.052 
(.001, .103) 
 
.020 
(0, .054) 
Q4B  Urban 
 
.078 
(.016, .141) 
.570 
(.456, .684) 
.308 
(.2, 417) 
.043 
(.009, .078) 
0 
- 
Reluctance to discuss 
sexuality/STI 
Q4C  Rural 
 
.020 
(.02, .02) 
 
.217 
(.137, .298) 
 
.574 
(.466, .682) 
 
.168 
(.084, .253) 
 
.020 
(0, .054) 
Q4C  Urban .003 
(0, .007) 
.223 
(.128, .318) 
.457 
(.353, .562) 
.314 
(.208, .421) 
.002 
(0, .004) 
Concern adolescent 
will assume parent 
condones premarital 
sex 
Q4D  Rural 
 
0 
- 
 
.247 
(.162, .332) 
 
.692 
(.598, .787) 
 
.061 
(.014, .108) 
 
0 
- 
Q4D  Urban .030 
(0, .08) 
.341 
(.232, .45) 
.428 
(.321, .535) 
.198 
(.104, 292) 
.001 
(0, .004) 
Concern adolescent 
will practice riskier 
sexual behavior 
Q4E  Rural 
 
0 
- 
 
.267 
(.176, .359) 
 
.539 
(.437, .641) 
 
.194 
(.143, 245) 
 
0 
- 
Q4E  Urban 
 
.035 
(0, .081) 
.352 
(.243, .462) 
.417 
(.31, .524) 
.196 
(.111, .281) 
0 
- 
Lack of parental 
education 
Q4F  Rural 
 
 
0 
- 
 
.182 
(.107, .257) 
 
.361 
(.265, .457) 
 
.364 
(.268, .461) 
 
.092 
(.031, .153) 
Q4F  Urban 
 
0 
- 
.183 
(.091, .275) 
.345 
(.247, .442) 
.346 
(.238, .454) 
.126 
(.048, .205) 
Request vaccine be 
deferred  
Q4G  Rural 
 
0 
- 
 
.112 
(.073, .15) 
 
.472 
(.382, .562) 
 
.416 
(.328, .504) 
 
0 
- 
Q4G  Urban 0 
- 
.161 
(.071, .251) 
.469 
(.36, .579) 
.331 
(.24, .423) 
.038 
(0, .084) 
Belief adolescent not at 
risk 
Q4H  Rural 
 
0 
- 
 
.162 
(.103, .22) 
 
.398 
(.303, .492) 
 
.441 
(.352, .529) 
 
0 
- 
Q4H Urban 0 .221 .348 .395, .037 
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 Never 
0% 
Rarely 
1-25% 
Sometimes 
26-29% 
Often 
51-75% 
Always 
>75% 
- (.123, .318) (.255, .44) (.285, .505) (0, .083) 
Parent won’t consent to 
vaccine 
Q4I  Rural 
 
0 
- 
 
.374 
(.246, .502) 
 
.539 
(.404, .673) 
 
.087 
(.015, .159) 
 
0 
- 
Q4I  Urban .028 
(0, .073) 
.401 
(.286, .516) 
.485 
(.377, .594) 
.054 
(.006, .101) 
.033 
(0, .078) 
Opposition for moral or 
religious reasons 
Q4J  Rural 
 
.278 
(.191, .365) 
 
.479 
(.385, .574) 
 
.222 
(.155, .29) 
 
.020 
(0, .054) 
 
0 
- 
Q4J  Urban 
 
.319 
(.211, .426) 
.415 
(.305, .525) 
.194 
(.107, .28) 
.071 
(.006, .136) 
.002 
(0, .004) 
Belief adolescent is too 
young  
Q4K  Rural 
 
0 
- 
 
.296 
(.235, .356) 
 
.581 
(.493, .668) 
 
.124 
(.053, .194) 
 
0 
- 
Q4K Urban 
 
.007 
(0, .018) 
.182 
(.089, .276) 
.329 
(227, .43) 
.472 
(.355, .589) 
.009 
(0, .02) 
Concern about negative 
media reports 
Q4L  Rural  
 
.122 
(.122, .122) 
 
.487 
(.418, .556) 
 
.371 
(.304, .437) 
 
.02 
(0, .054) 
 
0 
- 
Q4L Urban 
 
.024 
(0, .054) 
.585 
(.474, .696) 
.371 
(.259, .484) 
.018 
(.005, 030) 
.002 
(0, .004) 
 
Research Question #2: 
 
What knowledge do Georgia physicians enrolled in the VFC program have when 
providing the HPV vaccine to their female patients? 
 
To answer this research question, seven items assessing knowledge about HPV vaccine were 
asked of the respondents.  The majority of respondents answered the seven questions correctly.  
Most physicians (97.2%) answered correctly that the FDA approved the quadrivalent HPV 
vaccine for use in females aged 9-26 years of age.  This was followed by 94.8% who knew the 
FDA has approved the quadrivalent HPV vaccine for use in males for the same age group. Also 
receiving a high correct response (91.1%) were those who knew almost all cervical cancers are 
cause by HPV infections and 90.6% were correct that HPV causes genital warts in males and 
females.   The fact that HPV was a relatively common sexually transmitted disease was known 
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by 86.4%.  Seventy-nine point three percent of respondents were aware that females with a 
diagnosis of HPV infection can still receive the HPV vaccine.  The question receiving the lowest 
correct score of 76.7% asked if respondents were aware that most HPV infections resolve 
without medical intervention.  The findings from this survey suggest knowledge of HPV and 
HPV vaccine were well known by the majority of respondents.  
Research Question #5: 
 
What differences will emerge when the data are analyzed by urban vs. rural 
characteristics? 
 
   To answer research question #5, Hypothesis #2 was tested. 
 
Hypothesis #2: 
 
No statistical differences will be detected between perceived knowledge of physicians 
enrolled in VFC program who provide the HPV vaccine to females and geographic 
setting (urban vs. rural). 
 
 Due to missing cells in the response categories, tests of hypothesis could not be performed.  
However estimates of proportions and their standard errors were calculated and no statistical 
significance was detected between perceived knowledge of physicians enrolled in VFC program 
who provide the HPV vaccine to females and geographic setting.  Since confidence intervals 
were overlapping across response categories between urban and rural practice settings, no 
statistical differences were detected. 
Estimates of proportions and their standard errors to physician perceived barriers are listed 
in Table 17. 
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Table 17:   
Responses to Question #2 
Question True False Unsure 
Most HPV infections resolve w/out medical 
intervention (TRUE) 
Q2A  Rural 
.818 
(746, .890) 
.067 
(.010, .125) 
.114 
(.069, .159) 
Q2A  Urban 
 
.790 
(.703, .878) 
.101 
(.043, .159) 
108 
(.036, .180) 
HPV is a relatively uncommon sexually 
transmitted infection (FALSE) 
Q2B  Rural 
.190 
(.124, .258) 
 
.771 
(.704, .838) 
.038 
(0, .083) 
Q2B  Urban  .082 
(.019, .145) 
.896 
(.832, .960) 
.021 
(.007, .036) 
HPV causes genital warts in males and 
females (TRUE) 
Q2C  Rural 
 
.881 
(.822, .940) 
 
.042 
(0, .091) 
 
.077 
(.045, .108) 
Q2C  Urban 
 
.898 
(.834,  .963) 
.065 
(.009, .120) 
.036 
(.002,  .070) 
Almost all cervical cancers are caused by 
HPV infections (TRUE) 
Q2D  Rural    
.874 
(.805, .943) 
.038 
(0, . 083) 
.087 
(.034, .140) 
Q2D  Urban .929 
(.873, .986) 
.039 
(0, .085) 
.031 
(0, .064) 
FDA approved HPV vaccine for use in 
females age 9-26 (TRUE) 
Q2E  Rural 
.943 
(.892, .993) 
.019 
(0,  .050) 
.038 
(0, .077) 
Q2E  Urban 
 
.978 
(.946, 1.0) 
.020 
(0, .052) 
.001 
(0, .004) 
Females diagnosed with HPV infection 
should not be given the vaccine (FALSE) 
Q2F  Rural 
.019 
0, .050) 
.817 
(.748, .886) 
.164 
(.102,  .225) 
Q2F  Urban .066 
(.002, .128) 
.776 
(.679, .874) 
.158 
(.077, .240) 
FDA approved HPV vaccine for use in 
males for permissive use for  ages 9-26 
(TRUE) 
Q2G  Rural 
.943 
(.893,  .993) 
0 
- 
.057 
.007, .107 
Q2G  Urban 
 
.951 
(.903, 1) 
.036 
(0,  .083) 
.013, 
(.002, .024) 
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Research Question #3: 
 
What percentage of Georgia physicians enrolled in the VFC program administers the 
HPV vaccine to their female patients according to Advisory Committee on 
Immunization Practices (ACIP) published guidelines by providing the vaccine to their 
11 – 12 year old patients? 
 
ACIP guidelines recommend administering the vaccine to females between the ages of 11-
12 years of age (CDC, 2008).  To answer this research question, respondents were asked if they 
administered the vaccine to 11-12 year olds in their practice.   Of those who responded, only 
12% said they always administer the vaccine to this age group.  A response of always indicated 
the vaccine was given to more than 75% of female patients between the ages of 11-12 years.  
Approximately 31.1% of respondents state they often administer the vaccine to this age group.  
A response of often indicated the vaccine was given to 51- 75% of female patients between the 
ages of 11-12 years. One quarter of respondents (24.4%) administered the vaccine sometimes to 
this age group.  A response of sometimes indicated the vaccine was given to 26 -50% of female 
patients between the ages of 11-12 years.  Respondents who rarely administer the vaccine to this 
age group were 23%.  A response of rarely indicated the vaccine was given to 1 - 25% of female 
patients between the ages of 11-12 years.  Physicians who never administer the vaccine to any 
females in this age group were 8.1% indicating approximately one in ten Georgia physicians do 
not administer the vaccine according to ACIP guidelines.  Patterns for this analysis can be 
viewed in Table 18.  
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Table 18:   
Administer HPV According to ACIP Guidelines 
 11-12 y 
--------- 
n  (%) 
Never  (administers the vaccine to 0% of girls in this age group) 17  (8.1) 
 
Rarely  (administers the vaccine to 1-25% of girls in this age group) 
 
48 (23.0) 
 
Sometimes (administers the vaccine to 26 - 50% of girls in this age group) 
 
51  (24.4) 
 
Often  (administers the vaccine to 26 - 50% of girls in this age group) 
 
63  (30.1) 
 
Always (administers the vaccine to 76-100% of girls in this age group) 
 
25  (12.0) 
Research Question #5: 
 
What differences will emerge when the data are analyzed by urban vs. rural characteristics? 
 
   To answer research question #5, Hypothesis #3 was tested. 
 
Hypothesis #3: 
 
No statistical differences will be detected between percentage of Georgia physicians 
enrolled in VFC program who indicate they recommend the HPV vaccine to male 
patients, and geographic setting (urban vs. rural). 
 
Estimates of proportions and their standard errors were calculated and no statistical 
significance was detected between administering HPV vaccine to female patients according to 
ACIP guidelines of administering the vaccine to 11-12 year old females and geographic setting.  
Since confidence intervals were overlapping across response categories between urban and rural 
practice setting, no statistical differences were detected. 
 Table 19 depicts estimates of proportions and their standard errors. 
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Table 19:  
 Administer HPV According to ACIP Guidelines with Mean and CIs 
 11-12 y 
Urban 
11-12 y 
Rural 
Never   (administers the vaccine to 0% of 
girls in this age group) 
.123 
(.046, .2) 
.061 
(.003, .119) 
 
Rarely  (administers the vaccine to 1-25% 
of girls in this age group) 
 
.246 
(.159, .334) 
 
.273 
(.204, .343) 
 
Sometimes (administers the vaccine to 26-
50% of girls in this age group) 
 
.214 
(.133, .296) 
 
.175 
(.113, .238) 
 
Often  (administers the vaccine to 51-75% 
of girls in this age group) 
 
.286 
(.182, .39) 
 
.354 
(.219, .488) 
 
Always  (administers the vaccine to 76-
100% of girls in this age group) 
 
.094 
(.032, .156) 
 
.113 
(0, .225) 
 
 
Research Question #4: 
 
What percentage of Georgia physicians enrolled in the VFC program, indicate they 
will recommend the HPV vaccine to their male patients? 
 
The ACIP recommends "permissive use" of the HPV vaccine among males age 9-26 years 
(MMWR, May 28, 2010).   To answer this research question, respondents were asked if they 
recommended the vaccine to males in their practice and if so at what age was it recommended.   
Age grouping of male patients was broken down into categories of 9-10 years old, 11-12 years 
old, 13-17 years old and 18 – 26 years old.  Responses are listed in Table 20.   Of those who 
responded, only 10.9% said they always recommend the vaccine to 9-10 year old males. A 
response of always indicated the vaccine was recommended to more than 75% of male patients 
between the ages of 9-10 years.  Respondents who often recommend the vaccine to this age 
group were 10.4%.  A response of often indicated the vaccine was recommended to 51- 75% of 
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male patients between the ages of 9-10 years.  Respondents who sometimes recommend the 
vaccine to this age group were 10.9%.  A response of sometimes indicated the vaccine was 
recommended to 26 -50% of male patients between the ages of 9-10 years.  Respondents who 
rarely recommend the vaccine to this age group were 23.2%.  A response of rarely indicated the 
vaccine was recommended to 1 - 25% of male patients between the ages of 9-10 years.   
Physicians who never recommend the vaccine to any males in this age group were 40.8%.  A 
response of never indicated the vaccine was not given to anyone in this age group,  
Of those who responded to recommending the vaccine to 11-12 year old males, 23.7% said 
they always recommend the vaccine to 11-12 year old males. A response of always indicated the 
vaccine was recommended to more than 75% of male patients in this age group.  Respondents 
who often recommend the vaccine to this age group were 19.4%.  A response of often indicated 
the vaccine was recommended to 51- 75% of male patients between the ages of 9-10 years.  
Respondents who sometimes recommend the vaccine to this age group were 13.7%.  A response 
of sometimes indicated the vaccine was recommended to 26 -50% of male patients between the 
ages of 11-12 years.  Respondents who rarely recommend the vaccine to this age group were 
16.1%.  A response of rarely indicated the vaccine was recommended to 1 - 25% of male 
patients between the ages of 11-12 years.  Physicians who never recommend the vaccine to any 
males in this age group were 23.8%. A response of never, indicated the physician did not 
vaccinate anyone in this age group, indicating approximately one fourth of Georgia physicians 
do not recommend the vaccine according to ACIP guidelines to males age 11-12 years.   
Of those who responded recommending the vaccine to 13-17 year old males, 26.9% said 
they always recommend the vaccine to 13-17 year old males. A response of always indicated the 
vaccine was recommended to more than 75% of male patients in this age group.  Respondents 
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who often recommend the vaccine to this age group were 20.2%.  A response of often indicated 
the vaccine was recommended to 51- 75% of male patients between the ages of 13-17 years.  
Respondents who sometimes recommend the vaccine to this age group were 13.7%.  A response 
of sometimes indicated the vaccine was recommended to 26-50% of male patients between the 
ages of 13-17 years.  Respondents who rarely recommend the vaccine to this age group were 
15.4%.  A response of rarely indicated the vaccine was recommended to 1 - 25% of male 
patients between the ages of 13-17 years.   Physicians who never recommend the vaccine to any 
males in this age group were 17.8%.  A response of never indicated the physician did not 
vaccinate anyone in this age group suggesting approximately one of five Georgia physicians do 
not recommend the vaccine according to ACIP guidelines to 13-17 year old males. Responses 
are summarized in Table 20. 
Of those who responded to recommending the vaccine to 18-26 year old males, 22.4% said 
they always recommend the vaccine to 18-26 year old males. A response of always indicated the 
vaccine was recommended to more than 75% of male patients in this age group.  Respondents 
who often recommend the vaccine to this age group were 14.3%.  A response of often indicated 
the vaccine was recommended to 51- 75% of male patients between the ages of 13-17 years.  
Respondents who sometimes recommend the vaccine to this age group were 11.9%.  A response 
of sometimes indicated the vaccine was recommended to 25 – 50% of male patients between the 
ages of 18-26 years.  Respondents who rarely recommend the vaccine to this age group were 
15.7%.  A response of rarely indicated the vaccine was recommended to 1 - 25% of male 
patients between the ages of 18-26 years.  Physicians who never recommend the vaccine to any 
males in this age group were 13.8%.  A response of never indicated the physician  did not 
vaccine anyone in this age group suggesting approximately one of five Georgia physicians do not 
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recommend the vaccine according to ACIP guidelines to 18-26 year old males.  Responses are 
summarized in Table 20. 
Table 20:   
Recommend HPV to Boys by Age Group 
 9-10 y 
--------- 
 (%) 
11-12 y 
--------- 
 (%) 
13-17 y 
--------- 
 (%) 
18-26 y 
--------- 
 (%) 
Never   (administers the vaccine to 0% of 
boys in this age group) 
40.8% 23.2% 17.8% 13.8% 
 
Rarely  (administers the vaccine to 25% 
of boys in this age group) 
 
23.2% 
 
16.1% 
 
15.4% 
 
15.7% 
 
Sometimes (administers the vaccine to 
26-50% of boys in this age group) 
 
10.9% 
 
13.7% 
 
16.3% 
 
11.9% 
 
Often(administers the vaccine to 51-75% 
of boys in this age group) 
 
10.4% 
 
19.4% 
 
20.2% 
 
14.3% 
 
Always (administers the vaccine to 76-
100% of boys in this age group)  
 
10.9% 
 
23.7% 
 
26.9% 
 
22.4% 
Research Question #5: 
 
What differences will emerge when the data are analyzed by urban vs. rural 
characteristics? 
 
   To answer research question 5, Hypothesis #4 was tested. 
Hypothesis #4: 
 
No statistical differences will be detected between percentage of Georgia physicians 
enrolled in VFC program who indicate they recommend the HPV vaccine to male 
patients, and geographic setting (urban vs. rural). 
 
Estimates of proportions and their standard errors were calculated and no statistical 
significance was detected between recommending HPV vaccine to male patients, and geographic 
setting. Since confidence intervals were overlapping across response categories between urban 
and rural practice setting, no statistical differences were detected. 
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Estimates of proportions and their standard errors to physician perceived barriers are listed 
in Table 21 
Table 21:   
Recommend HPV to Boys According to ACIP Guidelines 
 Never Rarely 
 
Sometimes 
 
Often 
 
Always 
 
Q8A  Rural  
9-10 yr old 
.304 
(.213, .396) 
.288 
(.216, .36) 
.163 
(.124, .203) 
.081 
(.03, .133) 
.139 
(.106, .172 
 
Q8A  Urban 
9-10 yr old 
 
.394 
(.288, .501) 
 
.225 
(.129, .321) 
 
.118 
(.045, .19) 
 
.095 
(.031, .158) 
 
.076 
(.02, .131) 
  .    
Q8B  Rural  
11-12 yr old 
.163 
(.074, .253) 
118 
(.072, .165) 
.190 
(.118, .262) 
145 
(.07, .22) 
.360 
(.278, .44) 
Q8B  Urban 
11-12 yr old 
.171 
(.103, .24) 
.159 
(.078, .24) 
.17 
(.088, .253) 
.221 
(.124, .319) 
.186 
(.096, .276) 
      
Q8C  Rural 
13-17 yr old 
.143 
(.06, .227) 
.118 
(.072, .165) 
.159 
(.094, .225) 
.196 
(.111, .281) 
.359 
(.278, .44) 
Q8C  Urban 
13-17 yr old 
126 
(.066, 186). 
.122 
(.049, .196) 
.244 
(.142, .346) 
.215 
(.117, .313) 
.2 
(.108, .292) 
     . 
Q8D  Rural 
18-26 yr old 
.090 
(.015, .156) 
.141 
(.083, .199) 
.102 
(.054, .149) 
.113 
(.041, .185) 
265 
(181, .349) 
Q8D  Urban 
18-26 yr old 
.099 
(.048, .15). 
.145 
(.062, .228) 
.178 
(.095, .261) 
.139 
(.063, .216) 
.132 
(.059, .204) 
 
 
After completing all descriptive statistics and reviewing all data, a combination of three new 
variables were created.  The three new variables are: knowscore, barriers, and parental barriers.  
Knowscore measured the physician's knowledge as ascertained through question 2 on the survey.  
Question 2 contained seven sub-questions and for each correct response the physician was 
awarded one point.  The scores range from 0 to seven. 
The second new variable, barriers, measured the physician's perception of barriers as 
ascertained from question 3 on the survey.  For each barrier the physicians agreed with (agree or 
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strongly agree) the physician was awarded one point.  There are 12 listed barriers, with score 
range from 0 to 12. 
The third and final variable, parental barriers, measured the physician's perception of 
parental barriers as ascertained from question 4 on the survey.  For each parental barrier the 
physicians agreed with (agree or strongly agree) the physician was awarded one point.  There are 
12 listed barriers, so the scores ranged from 0 to 12. 
As each of these three new variables represents a new summative scale, Cronbach's alpha 
was calculated to assess the reliability of scales.  For the Knowscore scale consisting of seven 
items, Cronbach's Alpha = 0.744, which can be consisted moderately good.  For the Barrier Scale 
with 12 items, Cronbach's Alpha = 0.808, again, a moderately good reliability.  Finally, for the 
Parental Barrier Scale, consisting of 12 items, Cronbach's Alpha = 0.822, and provides 
moderately good reliability. 
Since the three new variables were created, summary statistics that incorporate the sample 
design (calculated with SAS Proc Surveymeans) are illustrated in Table 22.  
Table 22:   
Summary Statistics Across Counties 
Variable 
 
Mean(SE) Lower 95% limit Upper 95% limit 
Barrier 
 
4.18(0.25) 3.76 4.60 
Parental Barrier 
 
2.47(0.24) 2.06 2.88 
Knowscore 
 
6.16(0.10) 5.98 6.33 
 
Since the three new variables were created, summary statistics that incorporate the sample 
design (calculated with SAS Proc Surveymeans) are given in Table 23. 
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Table 23:  
 Summary Statistics Rural and Urban 
Variable Mean(SE) Lower 95% limit Upper 95% limit 
 
Rural 
   
Barrier 
 
3.77 (0.48) 2.98 4.61 
Parental Barrier 
 
2.42 (0.49) 1.58 3.23 
Knowscore 6.16 (0.25) 5.73 6.59 
 
Urban 
   
Barrier 
 
4.33 (0.28) 3.85 4.81 
Parental Barrier 
 
2.49 (0.27) 2.02 2.96 
Knowscore 
 
6.16 (0.10) 5.98 6.34 
 
After summary statistics incorporating the sample design were established, logistic 
regression analysis was performed to determine variables that may influence a physician's 
decision to not recommend the HPV vaccine to their patients.  There were two dependent 
variables of interest: females’ age 11-12 years and males age 11-12 years.  Table 24 refers to 
females not getting an HPV vaccine recommendation.   
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Table 24:   
Females Age 11-12 Not Getting HPV Vaccine Recommendation 
  
Effect 
 
Df Wald statistic P-value 
%Medicaid 
 
4 191.63 <0.001*** 
Physician gender 
 
1 3.946 0.047*** 
Knowscore 
 
1 0.216 0.641 
Barrier 
 
1 0.057 0.812 
Parental barrier 
 
1 6.721 <0.001*** 
 % Medicaid is most likely a spurious result due to only 2 providers not accepting Medicaid. 
 
The significant effect (p <  0.001) detected by having Medicaid as a payer sources is most 
likely a spurious result due to only two providers not accepting Medicaid.  A significant effect 
(p=0.047) was detected between physician gender and a female patient not getting a 
recommendation for HPV vaccine.  A second significant effect (p<0.001) was detected between 
parental barrier and a female not getting an HPV vaccine recommendation. 
Next, confidence limits on odds ratio was performed to further determine variables that may 
influence a physician's decision to not recommend HPV vaccine to their patients.  Refer to Table 
25 for estimated odds ratio and 95% confidence intervals.  
Table 25:  
 Confidence Limits on Odds Ratios for Not Getting HPV Recommendation 
Effect 
 
Estimated OR 95% C.I. for Odds Ratio 
Medicaid 1 vs. 5 (0% vs. 76-100%) 
 
<0.001 (<0.001, <0.001)  ***$$$ 
Medicaid 2 vs. 5 (1-25% vs. 76-100%) 
 
3.762 (0.268, 52.709)  NS 
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Effect 
 
Estimated OR 95% C.I. for Odds Ratio 
Medicaid 3 vs. 5 (26-50% vs. 76-100%) 
 
2.960 (0.772, 11.347)  NS 
Medicaid 4 vs. 5 (51-75% vs. 76%-100%) 
 
1.439 (0.315, 6.573)  NS 
Gender (female vs. male) 
 
3.071 (1.015, 9.293) *** 
Knowscore 
 
0.895 (0.562, 1.427)  NS 
Parental Barrier 
 
0.986 (0.881, 1.104)  NS 
Barrier 
 
1.154 (1.035, 1.285)  *** 
*** indicates statistical significance at alpha=0.05,  $$$- spurious result  (there are only 2 providers for less than 1% 
who state 0% Medicaid)   
 
Parental barrier was significant with an estimated odds ratio of 1.154. Of interest was the 
estimated odds ratio for female physicians to not recommend the HPV vaccine to their female 
patients of 3.071 indicating physician gender has an impact on the likelihood of vaccination.  
Other variables were not considered significant.   
The likelihood of physicians to not recommend the HPV vaccine to males’ ages 11-12 years 
was explored.  Logistic regression analysis was performed to determine variables that may 
influence a physician's decision to not recommend HPV vaccine to their male patients as shown 
in Table 26 for estimated odds ratio and 95% confidence intervals. 
Table 26:   
Males 11-12 Years Not Getting HPV Recommendation 
 
Effect 
 
Df Wald statistic P-value 
%Medicaid 
 
4 3.545 0.471 
Physician gender 
 
1 3.171 0.075 
Knowscore 
 
1 2.394 0.122 
Barrier 
 
1 0.156 0.693 
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Effect 
 
Df Wald statistic P-value 
Parental barrier 
 
1 2.592 0.108 
  
No significant effect (p < 0.05) was detected with any variable.  Confidence limits on odds 
ratio was performed to further determine variables that may influence a physician's decision to 
not recommend HPV vaccine to their male patients.  No significant effects were detected.  Refer 
to Table 27. 
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Table 27:   
Confidence Limits on Odds Ratios for Not Getting HPV Recommendation 
Effect Estimated OR 95% C.I. for Odds Ratio 
 
Medicaid 1 vs. 5 (0% vs. 76-100% 0.791 (0.173, 3.624)  NS 
 
Medicaid 2 vs. 5 (1-25% vs. 76-
100%) 
2.780 (0.218, 35.459)  NS 
 
Medicaid 3 vs. 5 (26-50% vs. 76-
100%) 
1.022 (0.256, 4.082)  NS 
 
Medicaid 4 vs. 5 (51-75% vs. 76%-
100%) 
0.740 (0.175, 3.121)  NS 
Gender (female vs. male) 2.529 (0.911, 7.021)  NS 
Knowscore 0.662 (0.392, 1.116)  NS 
Parental Barrier 1.039 (0.860, 1.256)  NS 
Barrier 1.132 (0.973, 1.317)  NS 
*** indicates statistical significance at alpha=0.05. 
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Chapter 5 
SUMMARY, DISCUSSION, AND CONCLUSIONS 
The purpose of this study was to examine the prevalence of Georgia physician intention and 
administration of HPV vaccine to 11-12 year-old girls and intention to recommend the 
quadrivalent HPV vaccine to 11-12 year old boys.  The study examined the attitudes and beliefs 
of Georgia physicians toward administering HPV vaccine and assessed perceived knowledge, 
barriers, practices, and adherence to ACIP guidelines and recommendations regarding HPV 
vaccination.  A distinction between urban and rural counties was examined to determine if there 
were differences. 
Summary of Findings 
The response rate for this study was 82.6%, with physicians and key informants representing 
Georgia physicians in the VFC program who administer HPV vaccine to their male and female 
patients.  The diverse representation of the respondents included 51.4% White, 22.6% Asian and 
18.4% African American.  Latino’s were noted to be 9.5% of respondents.  Males accounted for 
51% and females were 49% of respondents.  Respondents practicing in rural counties represented 
18.8% and urban county respondents were 81.2%.  Practice size ranged from single physician 
practices to one practice with more than 26 physician providers. 
Research Question #1: Descriptive analysis of data showed 64.2% believed the most 
important barrier for not vaccinating was lack of adequate reimbursement for HPV vaccination.   
The barrier of inadequate reimbursement was followed by 63.2% citing the cost of stocking the 
HPV vaccine and 60.8% believing the upfront or initial cost of purchasing the private stock HPV 
vaccine was a barrier.  Only 9.9% had concerns about the safety of the HPV vaccine.   Many 
physicians commented on the lack of reimbursement by private insurance companies. Research 
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by Kahn et al. (2009) with Texas physicians yielded nearly identical findings as it pertains to 
barriers of cost and reimbursement.   In the Texas study, 67.1% noted lack of payment by some 
insurance companies as a barrier compared with 64.2% in this research (Kahn et al., 2009).  This 
is especially important for those physicians with practices that do not contain many VFC patients 
where cost of the vaccine is covered.  Gudeman (2007) had similar findings and observed that 
while VFC programs work for those who qualify; those who do not qualify for the VFC program 
do not benefit from vaccination and reimbursement remains an issue.  As one physician noted: 
“I would give more vaccine if insurance paid for it.  It is difficult to ask a mother 
to pay $350.00 for a vaccine not required for school and not covered by her 
insurance.” 
 
The most significant parental barrier to vaccination according to Georgia physicians was the 
request that HPV vaccine be deferred until the female patient was older.  This barrier was noted 
by 89.9% of respondents followed by lack of education/understanding of the HPV vaccine at 
83.2%.  Parental opposition to HPV vaccination for moral or religious reasons was a barrier to 
less than one in four physicians.  Previous research (Charo, 2007; Daley et al., 2006; Katz et al., 
2009; Tissot et al., 2007) suggested strong religious beliefs lead to a delay or refusal of vaccine 
was not found in this research.  One Georgia physician summed what others stated by observing:  
“I have never had a mother tell me it was against her religious belief to not 
vaccinate with this vaccine.  I think the press made a big deal in the beginning 
when the vaccine was new, but it is not true.” 
 
Research Question #2:  The overall knowledge about HPV and who could receive the HPV 
vaccine was well known by most respondents.   Over 90% of respondents were aware that the 
FDA approved the quadrivalent HPV vaccine for males and females, that almost all cervical 
cancers are caused by HPV, and that HPV also causes genital warts in both sexes.  The 
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remaining survey questions were answered correctly by over 75% of respondents and pertained 
to knowledge that HPV is a sexually transmitted disease which usually resolves without medical 
intervention and that females with an HPV may still receive the vaccine.  These combined scores 
indicate an overall high rate of knowledge among respondents.  These findings of Georgia 
physicians are similar to finding by Daley et al. (2010) in a national survey of physician 
knowledge.   
Research Question  #3: Vaccinating females according to ACIP guidelines at age 11-12 
years was performed by 12% who stated they always administer the vaccine to this age group.  
Many providers who administer the vaccine stated they use reminders to assist with vaccination 
and use a positive, professional approach:  
“I tell the mom I am going to vaccinate at the next visit, then at that visit I have a 
matter of fact approach about it, no big deal, I vaccinate and talk about how this 
vaccine protects against cervical cancer and that I wish there were more 
vaccines that protected against other types of cancer.  I tell the mother there are 
two more shots and that my office will remind her when to bring her daughter 
back.” 
 
Other physicians were less compliant when vaccinating 11-12 year old females.  Indeed, 
30.1% stated they were successful with 51-75% of their patients, and about one-quarter of 
respondents was successful with 26 – 50% of their female patients in this age group.  Multiple 
physicians stated parental concern about the age of the child as a barrier, noting: 
“I recommend the vaccine beginning at age 10 but moms have different reasons 
why they want to wait to have their daughters vaccinated.  Some wait until their 
daughter goes to high school in case she talks about it with her friends and I’ve 
had some moms that wait until their daughter start their menstrual cycle.  If 
insurance does not cover it, moms will often refuse the vaccine.” 
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Physicians who never vaccinate females at 11-12 years of age were 8.1%.  One physician 
summed what others who did not vaccinate at this age noted: 
“Most women wait until their daughter is at least 13 years old and then they 
bring her in for the vaccine.  It is less of a concern to the mom at that age.” 
 These findings of Georgia physicians are similar to finding by Daley et al. (2010) in a 
national survey of physician vaccination.  Other researchers (Kahn et al., 2008; Katz et al., 200; 
Ko et al., 2010 & Shan et al., 2007) has similar findings indicating physicians appear to be 
delaying vaccinating until the adolescent is past of age of 12 and not vaccinating according to 
ACIP guidelines. 
Research Question #4:  Analysis of the data revealed less than one-quarter of physicians 
always recommend the HPV vaccine to male patients at any age.  The fewest physicians 
recommend it to males 9-10 years with only 10.9% recommending.  In addition, the physicians 
who stated they never recommended the vaccine was surprising with 40.8% stating they never 
recommend HPV vaccination to 9-10 year olds.   The data were slightly better for 11-12 year old 
males with 23.7% stating they always recommend the vaccine and 23.2 % stating they never 
recommend the vaccine to 11 -12 year old males.  Other researchers (Weiss et al., 2010) who 
studied physicians currently administering HPV vaccine to females suggest physicians supported 
the concept of vaccinating males for the benefits it imparts on both sexes.  Recommending the 
vaccine early and to both sexes was seen as important.  By doing so, patient and parent can be 
educated about the HPV vaccine and vaccination may occur at the next annual visit. As one 
physician commented: 
“It is difficult enough to get girls vaccinated, I am just now starting with the 
boys.  I tell them I think they should have it but they don’t see it as important or 
something they need right now.” 
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Research Question #5:  No difference emerged when the data were analyzed by urban or 
rural geographic location.  This may be attributed to sample size but the response rate for this 
study was 82.6%.  Data reveals that geographic location of physician practice does not appear to 
impact HPV vaccine administration. 
After completing analysis for the research questions with no significant findings, three new 
variables were created to reveal what may cause physicians not to recommend HPV vaccination.  
From these three new variables, logistic regression was used to determine that female physicians 
and parental barriers made it more likely that female patients 11-12 years of age would not 
receive a recommendation for HPV vaccination.  There was no effect on not recommending the 
HPV vaccine to male patient’s age 11-12 years.   
  The findings that method of payment, such as having a low percentage of patients with 
Medicaid as a payer source, appears to be a spurious result because less than 1% of respondents 
were in this category.    
To summarize the findings, none of the original variables (administering the HPV vaccine to 
11-12 year old females according to ACIP guidelines, recommending the HPV vaccine to males, 
barriers, or knowledge) impacted differences among urban and rural physician providers in 
Georgia although female physicians and parental barriers appear to be make it more likely that 
11-12 year of female patients will not receive a recommendation for vaccination.   
Health Belief Model and Research Findings 
HPV vaccination by physicians within the framework of the Health Belief Model was used 
to inform this research.  The Health Belief Model views key determinants of health and illness to 
be individual health behavior (Becker, 1974; Glanz, et al., 2008; Rosenstock, 1974). Using the 
Health Belief Model, perceived susceptibility manifested by physician knowledge that patients 
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are at risk for HPV infection was evident by the correct responses to the survey.  Physicians 
correctly answered survey questions pertaining to HPV infection and the immense prevalence of 
the virus within the population.   
Perceived susceptibility 
 As previously noted by Brown (2005), the cumulative prevalence of HPV infection in 
sexually active adolescent females is high, and physicians must educate parents and adolescents 
about the risks if improved vaccination rates are to be achieved. Physician education of parents 
can increase the parent’s understanding of adolescent susceptibility.  The knowledge could lead 
to increased HPV vaccination.  This is vital because 80.8% of respondents to this survey 
indicated parents do not believe their adolescent to be at risk for HPV.  These finding suggests 
low perceived susceptibility to the human papillomavirus when in fact over 70% of sexually 
active men and women will acquire a genital HPV infection during their lifetime (CDC 2010). 
Perceived severity 
Perceived severity of HPV infection leading to problems of genital warts and possible cervical 
cancer were known by the majority of physicians in this survey.  Most HPV infections are 
asymptomatic, transient, and resolve without medical intervention (CDC 2010).  Most physicians 
were aware of this fact as was noted in this research and studies by Daley et al. (2010) and Kahn 
et al. (2009).  These studies also showed a high adoption rate of vaccination by physicians with 
most physicians aware of several key aspects of HPV epidemiology.  While not all adolescents 
will go on to have genital warts or develop cervical cancer, submitting accurate information to 
physicians will allow them to make informed decisions about vaccination and could prevent 
many future cases.   
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Perceived benefits 
Keeping within the framework of the Health Belief Model, perceived benefits of vaccinating 
which reduces the risk of HPV infections was known by most respondents in this survey.  
Nevertheless, for the benefits of vaccination to be realized, the vaccine must be administered 
before the onset of sexual activity and exposure to HPV virus (Markowitz et al., 2007) if it is to 
be most effective.  Research by Daley et al. (2010) note physicians are well aware of HPV and 
HPV vaccine but at least 25% of physicians in that study do not follow ACIP guidelines of 
vaccinating 11-12 year olds and often wait until after 13 years of age.  Their findings were 
similar to findings in this research of Georgia physicians which noted 8.1% never vaccinate and 
23% rarely vaccinate 11-12 year olds.  
When placed in the framework of the Health Belief Model, there are opportunities to 
increase HPV vaccination rates of this age group.  For example, school entry laws create a 
perceived benefit of vaccination, yet HPV vaccination is not mandated in Georgia or most other 
states (Charo, 2007).  Currently in Georgia, students must receive or show proof of having 
tetanus, diphtheria, pertussis, hepatitis B, polio, measles, mumps, rubella and varicella 
vaccinations or have a religious exemption before attending school (Georgia Department of 
Education, 2010). This is not the case for HPV vaccine.  By mandating HPV vaccine for middle 
school entry, a perceived benefit is implied, particularly if physicians support the school 
mandate.  However, the American Academy of Family Physicians note in their 2007 policy 
statement that they would recommend the vaccine as a mandate for school admission  only after 
“long term safety with widespread use, stability of supply, and economic issues have been 
clarified”  (AAFP 2007).  The position of the AAFP has not changed and there is still no 
recommendation to include HPV vaccine as part of school mandated vaccines (AAFP, 2011). 
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In one survey by Horn, Howard, Waller, and Ferris, (2010), most parents supported 
mandatory vaccination programs in general, but less than half who responded to the survey felt 
the HPV vaccine should be mandated.  The main reasons for nonsupport were that it would 
infringe on their rights, that the vaccine had not been well studied, and had too many adverse 
effects.   
Perceived barriers 
Within the framework of the Health Belief Model, barriers identified by this research are 
viewed as components that converge to yield the final decision to vaccinate or not to vaccinate.   
For example, cost of the vaccine was cited as just one barrier by many physicians who took part 
in this research.  Brewer and Fazeka (2007) noted variables associated with HPV vaccine 
initiation in multivariate analyses included the barrier of the physician’s ability to store HPV 
vaccine and perceived barriers to obtaining HPV vaccine.   
For parents, cost of missed working hours and transportation costs must also be considered.  
Many adolescents do not have private health insurance that covers the cost of the vaccine.  Those 
that may be eligible may not take advantage of public programs such as Medicaid or VFC. 
Another barrier within the framework of the Health Belief Model is under-utilization of 
health care services by male and female adolescents.  If HPV vaccine education is to occur 
during the physician visit, then the visit must first occur.  Then the physician can impart his 
beliefs regarding perceived susceptibility and severity of disease, and perceived benefits of 
vaccination.  The AMA (2011) recommends three visits from age 11 -21 years.  The first visit is 
recommended between the ages of 11-14, one visit for ages 15-17 and the last visit before the 
21st birthday.  Within the framework of the Health Belief Model, if the physician perceives the 
severity of HPV and the adolescent’s lifetime susceptibility of the disease, and if the physician 
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has the self-efficacy to administer the vaccine, then the physician will use this visit as a cue to 
action to recommend and administer the vaccine provided the adolescent makes the visit. 
Cues to action to vaccinate and self-efficacy 
Cues to action to vaccinate and self-efficacy were not explored in depth in this research but 
should be the subject of future research.  McCave (2010) noted vaccination rates improved when 
the physician had a personal belief in the positive impact of the HPV vaccine and office 
strategies which supported vaccination.  Effective physician strategies for HPV vaccine delivery 
(Tissot, et al., 2007) indicated multiple office approaches improved vaccination rates.  
Implementing office-based procedures and policies, providing education and information 
opportunities to physicians and parents, and ensuring endorsement of HPV vaccination by 
influential organizations, were noted to be effective.   
Although the main purpose of this research was to provide a quantitative assessment of 
Georgia physician intention and administration of the HPV vaccine to 11-12 year-old girls and 
intention to recommend the HPV vaccine to 11-12 year old boys, a rich compilation of 
qualitative information accompanies the data set.  This will provide the basis for future analysis 
and reporting and further contribute to the knowledge base in this area of public health. 
Discussion of Findings 
Despite national recommendations for universal vaccination of 11-12 year old females, 
approximately one in ten Georgia physicians (12%) who responded to this survey reported they 
always vaccinate females in this age group.  The number increases to one in five (22.9%) who 
reported  they always vaccinate females age 13-17 years, suggesting parents or physicians may 
be delaying vaccination until females are older than 12 years.  This study was conducted five 
years after the ACIP recommendation to vaccinate females at 11-12 years (Markowitz et al., 
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2007) suggesting additional efforts are needed to improve physician awareness of and adherence 
to national recommendations.   
This study found 50.5% of Georgia physicians always recommended HPV vaccine to 11-12 
year old females which was similar to the findings of a Texas study (Kahn et al., 2009) where 
48.5% reported they always recommend HPV vaccination at this age.  A national internet and 
standard mail survey of physicians by Daley et al. (2010) also indicated 56% of physicians 
strongly recommend the vaccine to this age group.  As the girls become older, this study 
indicated 69.9% always recommend the vaccine to 13-17 year olds which is very similar to 
Texas physicians (Kahn et al., 2009) where 64.4% always recommend.  However the national 
study by Daley et al. (2010) had a higher recommendation rate of 82%.  
 These findings suggest more physicians strongly recommended HPV vaccination to patients 
13 years and older and was the finding in this research of Georgia physicians.  Research by 
Daley et al. (2010) to a national group of pediatricians and family practice physicians indicated 
fewer respondents strongly recommended HPV vaccination for 11-to 12-year old girls than for 
older female patients. Among pediatricians, 57% said they recommended the vaccine for that age 
group, but 90% recommended the vaccine for their 13- to 15-year old patients.  Findings from 
the national study were similar to findings of Georgia physicians from this research.  
Perceived barriers to HPV vaccination indicated financial barriers and parent opposition as 
reasons for not vaccinating.  Financial constraints were found to be a barrier in this research by 
the majority of physicians.  This was also found to be a barrier in research by Kahn et al (2009) 
statewide survey of Texas physicians, research by Daley et al. (2010), in a national survey of 
physicians.   The national survey of physicians found that vaccine costs and insurance coverage 
were the main financial barriers to strongly recommending HPV vaccination.  
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More than half (59.4%) Georgia physicians reported insufficient insurance coverage for the 
vaccine as a barrier to their practice when offering the vaccine.  HPV vaccination coverage by 
both public and private health care plans remains an important issue if Georgia vaccination rates 
are to increase.  Physicians had experienced parental barriers to HPV vaccination, and most of 
these had been anticipated by physicians in studies conducted before HPV vaccine licensing 
(Daley et al., 2006; Dempsey & Davis, 2006).  Findings suggest that providing physicians with 
information about HPV vaccines and with strategies to educate parents while addressing specific 
parental concerns will be important in overcoming barriers.  State and local immunization 
coalitions that focus on regaining public trust in vaccines and that encourage accurate and 
responsible journalism will be essential in efforts to increase HPV vaccination rates. 
The physician perceived parental barrier that the vaccinated child would practice riskier 
sexual behavior was noted by 69.7% in this research.  However, research published in the 
American Society for Colposcopy and Cervical Pathology had a different finding and noted 
“most parents do not think the HPV vaccine would actually encourage sexual activity in their 
children” (Ferris, Cromwell, Waller, & Horn, 2010, p. 179).  In their study, most parents thought 
the HPV vaccine would not alter their children’s reproductive behavior.  Their research indicated 
only a very small minority of parents believed it might lead to riskier sexual behavior.  Older 
parents and parents with older adolescents were the ones more likely to think that HPV vaccine 
encourages riskier sexual behavior.  In addition, parents with a greater number of daughters were 
concerned about risky sexual behavior. Their study found that these children became sexually 
active shortly after receiving the vaccine by coincidence, and as a result, the vaccine was blamed 
for this action.  However, research by Daley et al. (2010) indicated parental concern about HPV 
vaccination was also a barrier; with 39% of pediatricians and 43% of family physicians reporting 
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that parents worried that vaccination against a sexually transmitted infection may encourage 
earlier or riskier sexual behavior. The survey also found that 22% of pediatricians and 23% of 
family physicians reported that parents of their 11- to 12-year-old patients were upset that they 
were offering the vaccine to that age group. Eighteen percent of pediatricians and 29% of family 
physicians reported that at least one fourth of parents of 11- to 12-year-old patients refused HPV 
vaccine (P < .01). Common reasons for parent refusals were that the vaccine was too new, the 
child was too young, and lack of health insurance for HPV vaccination. 
Georgia physician’s attitudes about vaccinating males indicate approximately one quarter 
Georgia physicians always recommend HPV vaccine to male patients.  However, findings were 
different when compared to recommendations for vaccinating males, with 42% of Texas 
physicians (Kahn et al., 2009) indicating they were extremely likely to recommend the vaccine to 
11-12 year old males.   
  Most physicians stated lack of payment as a barrier to vaccinating males. While the number 
of physicians who always recommend the vaccine is less than those who always vaccinate 
female patients, physicians may be more likely to recommend HPV vaccine as more information 
becomes available about HPV related diseases in men. Nevertheless, male HPV vaccination 
raises unique issues and specific educational messages for physicians, parents, and males will 
need to be developed if vaccination rates are to increase.   
In Georgia, female physicians and parental barriers are factors associated with not 
recommending the HPV vaccine to 11-12 year old females.  In a national study by Daley (2006) 
surveying pediatrician’s knowledge and attitudes regarding HPV vaccination, 97% of female 
pediatricians versus 81% of male pediatricians reported feeling comfortable discussing sexuality 
with female patients.  In a follow up study by Daley et al. (2010) female family physicians were 
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more likely to give the vaccine than male family physicians.  Ko et al (2010) findings suggested 
female, primary care, and community and private practice physicians were associated with 
increased vaccination. Physicians who took part in this research also noted the greatest barrier to 
vaccination was reimbursement concerns.  Reimbursement was also a barrier for Georgia 
physicians. 
Study Strengths and Limitations 
This study provides researchers and immunization professionals with a comprehensive 
examination of the prevalence of Georgia physician intention and administration of HPV vaccine 
to 11-12 year-old girls, and their intention to recommend HPV vaccine to 11-12 year old boys.  
The study examined the attitudes and beliefs of Georgia physicians toward administering HPV 
vaccine and assessed perceived knowledge, barriers, practices, and adherence to ACIP guidelines 
and recommendations regarding HPV vaccination.   
The major strength of the study is its response rate of 82.6% from the sampling plan (n=264) 
of Georgia physicians who administer the HPV vaccine.   The researcher drew the sample from a 
database maintained by the Immunization Section of the Division of Public Health within the 
Department of Community Health and the database is updated annually.   A second strength of 
the study was the survey tool itself.  We adopted a previously validated survey tool developed by 
researchers from the Moffitt Cancer Center and tested by Vadaparampil (2009) from a 
nationwide survey.  
A limitation to this study is the possible difference in physician response in larger practices 
from those who were smaller practices or practiced alone.  For example, in an office practice 
with two or more physicians, only one physician was asked to complete the survey.  It is not 
known if asking all physicians in a practice would yield the same results as asking one physician 
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and this could be the basis for further research.  However, researchers of physician surveys 
suggest bias may be of less concern in physician surveys than in surveys of the general public 
and physicians tend to be fairly homogeneous with respect to knowledge, training, attitudes, and 
behaviors (Kellerman & Herold, 2001).  It is also possible that some survey respondents, while 
authorized by the physician to respond, might not have been the correct key informant with 
appropriate knowledge and could have reported inaccurate responses.  The database obtained by 
the Immunization Section of the Division of Public Health within the Department of Community 
Health may not have included all physicians who are on the VFC list and who administer the 
HPV vaccine. Lastly, the study assessed physician-reported behavior but did not observe actual 
vaccination practices.  
Implication for Public Health Programs, Policies, and Allocation of Resources 
In Georgia, most childhood immunizations (81%) are administered in the private sector at 
physician offices (Georgia Department of Community Health, 2010).  Public health must have a 
firm understanding of who is recommending and administering vaccines in order to target 
messages and action.  As the Mission and Vision of the Immunization Section of the Georgia 
Division of Public Health is to “… work to increase immunization rates for all Georgians and 
decrease the incidence of vaccine-preventable diseases” (DCH, 2010), it is important to have 
information about the attitudes and beliefs of Georgia physicians toward administering the HPV 
vaccine and assess perceived knowledge, barriers, practices, and adherence to ACIP guidelines 
and recommendations.  Future efforts may focus on female gender of physician and parental 
barriers with regards to recommendation of the vaccine to 11-12 year old girls, to guide 
strategies. 
   
100 
 
The Immunization Section of the Georgia Division of Public Health will be informed of 
findings to assist with future immunization program outreach.  As noted by Daley et al. (2010) 
physicians appear more likely to recommend the HPV vaccine at older ages and vaccination may 
not occur at the age recommended by national guidelines.  Therefore, educational materials 
should highlight ACIP guidelines and recommendations of HPV vaccination.  The finding that 
financial barriers exist will assist the Immunization Section target the release of VFC vaccine 
and information to areas where providers may have experienced difficulty in vaccinating 
uninsured and under-insured children.  The finding of female physicians being less likely to 
recommend the HPV vaccine to 11-12 year old female patients will be shared with local medical 
organizations to determine best approaches for addressing this finding and encouraging 
vaccination. 
According to Healthy People 2010 (USDHHS, 2000), programs that employ social 
ecological model  approaches for immunization are becoming more prevalent, with policy 
intervention at the societal level being one strategy to impact change.  Policy that includes the 
option of creating a state mandate in Georgia would improve overall HPV vaccination rates 
among the target population. However, it is not certain that physicians and other key 
stakeholders are prepared to endorse a state mandate in Georgia.   
 Engaging physicians in the policy debate of a future state mandate will be necessary if 
higher rates of HPV vaccine uptake among the population are to be realized and if policy is to 
change.  Although only 15.1% of physicians surveyed believed not requiring a school mandate to 
be a barrier, the fact remains that overall vaccination rates according to ACIP guidelines is 38% 
in Georgia (MMWR 2010). 
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This study provides the first comprehensive examination of the prevalence of Georgia 
physician intention and administration of the HPV vaccine to 11-12 year-old girls, and their 
intention to recommend the HPV vaccine to 11-12 year old boys.  While the findings are similar 
to other studies completed nationally and in different states, this is the first such study to be 
conducted in Georgia.  As such, its contribution to Georgia’s public health’s promoting 
comprehensive adolescent immunization is important.  It serves as a snapshot of what is 
happening in Georgia and as baseline data for future studies. 
 The Office of Immunization within the Georgia Division of Public Health will be able to 
use data from this and future studies to create a baseline for vaccine outreach, marketing 
campaigns, grant activities, and legislative education.  Having baseline immunization data can be 
the first step in creating policy that targets those who provide the majority of immunization. It 
can only do this by engaging the physicians who administer the most vaccine.  Having a better 
understanding of physician knowledge, attitude and vaccination practice is the first of many steps 
toward improved immunization rates.   By sharing and following examples of others, physicians 
can customize messages and parent education to better meet the needs of their distinctive patient 
population. As one physician noted: 
“I have no idea what others do (in their office), I could be leading the pack or 
bringing up the rear.” 
 
Public health practitioners should strive to increase the number and percentage of males and 
females who receive HPV vaccine to comply with ACIP guidelines and to promote overall health 
and wellness among the population.  One local activity “Tea and HPV” that appears to have met 
with moderate success will be shared across the state and may also prove useful in other states to 
increase HPV vaccination rates.  “Tea and HPV” utilized the school setting as a place to bring 
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young girls together with their mothers to learn more about the virus and vaccine.  The middle 
school was opened after school hours to female students in the fifth and six grade and their 
mothers.  The lunchroom was decorated and parents were served light refreshments by their 
daughters.  Public Health nurses provided a brief presentation on HPV and remained to answer 
any questions.  A similar venue can be done with boys and their fathers. 
Suggestions for Future Research 
Although the main purpose of the current study was to provide a quantitative assessment of 
Georgia physician intention and administration of the HPV vaccine to 11-12 year-old girls and 
their intention to recommend the HPV vaccine to 11-12 year old boys, a rich compilation of 
qualitative information accompanies the data set.   Future efforts may focus on female gender of 
the physician and parental barriers with regards to recommendation of the vaccine to 11-12 year 
old girls, to guide strategies.  Focus groups of female physicians with public health professionals 
facilitating may lead to an expansion of reasons given for not recommending the vaccine.  This 
will be beneficial if efforts to increase rates are to be realized in Georgia.  It may also be useful 
to include parents in separate focus groups to allow them freedom to express their concerns and 
barriers to vaccinating their younger daughters.  Efforts to explore barriers of physicians and 
parents may lead to modifications in social media and actions that could be applied to other 
states.  
Other areas of focus for researchers may include examining how the HPV vaccine is 
supplied to determine if providing the vaccine in smaller unit packages has an impact on the 
physician barrier of cost of stocking the vaccine.  Finally, another focus may be exploring how 
public health communicates vaccine information and education to physician offices. While 
92.5% of respondents indicated they received vaccine information from state and location 
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immunizations programs, a knowledge gap remains.  Educating the physician about the VFC 
program and which patients may qualify for this program is another area for future research. 
Most physicians in this study indicated financial barriers kept them from recommending and 
administering the HPV vaccine more often to their patients.  The VFC program is available to 
reimburse the physician for providing the vaccine to children who do not have insurance or who 
have insurance that does not cover the cost of HPV vaccine.  As all physicians in this study were 
VFC providers and may not be aware of how this program could help their patients who do not 
have insurance. Further research to explain why physicians are not utilizing this program to 
cover the cost of vaccine for their uninsured and underinsured patients, should be explored.  The 
VFC program is a federal program and findings may be applicable to other states. 
The current practice in the Georgia Immunization Sections is to provide new vaccine 
information and communications through telephone fax and email to the physician office.  
However, it is not known if all physician locations receive this information or if the telephone 
fax or email address is current.  Indeed, when physicians change office location, retire, or move 
to another practice, this information may not be available to the Georgia Immunization Section.  
In this case, current information on vaccine changes will not be known to the physician.   An 
annual review of the VFC provider list to verify telephone fax and email information is 
necessary to ensure all physicians have access to the most current vaccine information and can 
apply the information at their practice. 
Conclusion  
This study was intended to provide an assessment of HPV vaccination by Georgia 
physicians to assess perceived knowledge, barriers, supports, practices, and adherence to ACIP 
guidelines and recommendations.  A proportionate stratified random selection method was 
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utilized to survey pediatricians, family physicians, gynecologists, and internal medicine 
physicians in Georgia.  The final sampling frame included 264 (n=264) physicians who 
administered the HPV vaccine, 62 in rural counties and 202 in six urban counties. Response rate 
to the survey was 82.6% yielding a high degree of reliability.  
As a result of this study, 64.2% believed the most important barrier for not vaccinating their 
female patients was lack of adequate reimbursement.  The most significant parental barrier to 
vaccination according to 89.9% was the request that HPV vaccine be deferred until the female 
patient was older, confirming female adolescents ages 13 to 17 are getting vaccinated in higher 
proportions than their pre-adolescent counterparts.   
Knowledge about HPV and who could receive the vaccine was correctly known by >90% of 
respondents.  Vaccinating females according to ACIP guidelines at age 11-12 years was 
performed consistently by only 12% of respondents.  Less than one quarter of physicians 
consistently recommend HPV vaccine to male patients at 11-12 years of age. 
No difference emerged when the data were analyzed by urban or rural geographic location.  
Three new variables created revealed through logistic regression that female physicians and 
parental barriers made it more likely that female patients 11-12 years of age would not receive a 
recommendation for HPV vaccination.   
This study adds to existing research highlighting the importance of considering barriers and 
supports, particularly the influence of financial barriers. It also points to the significance of 
personal beliefs, specifically having a belief that the HPV vaccine will have a positive impact on 
young men and women’s lives.  Future efforts may focus on female gender of the physician and 
parental barriers with regards to recommendation of the vaccine.   Scholars from public health 
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will be at the research table and join others as part of the creation of a new body of literature with 
state-wide implications. 
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APPENDICES 
A.  MAP OF GEORGIA BY PUBLIC HEALTH DISTRICTS 
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B.  IRB Approval Letter 
 
Georgia Southern University 
Office of Research Services & Sponsored Programs 
 
Institutional Review Board (IRB) 
 
Phone:  912-478-0843                                                                       Veazey Hall 2021 
                                                                                                           P. O. Box 8005 
Fax:  912-478-0719                IRB@GeorgiaSouthern.edu               Statesboro, GA. 30460                                 
 
To:                  Betty Dixon,      103 Gloucester Road,         Savannah, GA. 31410 
             John S. Luque,  Robert Vogel, Stuart Tedders 
 
CC:             Charles E. Patterson,  
             Vice President for Research and Dean of the Graduate College 
  
From:             Office of Research Services and Sponsored Programs 
                        Administrative Support Office for Research Oversight Committees,  (IACUC/IBC/IRB)                 
Date:             October 4, 2010 
Expiration      May 1, 2011 
Date: 
Subject:          Status of Application for Approval to Utilize Human Subjects in  Research 
 
After a review of your proposed research project number H11059 and titled “An Assessment of HPV Vaccination 
by Georgia Physicians: Perceived Knowledge, Barriers, Supports, Practices, and Adherence to ACIP 
Guidelines AND Recommendations,” it appears that (1) the research subjects are at minimal risk, (2) appropriate 
safeguards are planned, and (3) the research activities involve only procedures which are allowable.  You are 
authorized to enroll up to 349 subjects. 
 
Therefore, as authorized in the Federal  Policy for the Protection of Human Subjects, I am pleased to notify 
you that the Institutional Review Board has approved your proposed research. 
 
This IRB approval is in effect for until May 1 2011.  If at the end of that time, there have been no changes to the 
research protocol; you may request an extension of the approval period for an additional year.  In the interim, please 
provide the IRB with any information concerning any significant adverse event, whether or not it is believed to be 
related to the study, within five working days of the event.  In addition if a change or modification of the approved 
methodology becomes necessary, you must notify the IRB Coordinator prior to initiating any such changes or 
modifications.  At that time, an amended application for IRB approval may be submitted.  Upon completion of your 
data collection, you are required to complete a Research Study Termination form to notify the IRB Coordinator, so 
your file may be closed. 
Sincerely, 
Eleanor Haynes 
Eleanor Haynes 
Compliance Officer 
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C.  Sampling Frame 
 
Selection method: PPS without replacement – Original Sampling Frame 
Obs 
County 
type County name Pop 2000 Pop 2009 Public Health District 
Number 
prov 
Selection 
Prob Sampling Weight 
1 
Rural Wilkinson 
County 
10220 10076 5-2 North Central 
(Macon) 
1 0.04255 23.5000 
2 Rural Berrien County 16235 17044 8-1 Valdosta 2 0.08511 11.7500 
3 Rural Hancock 
County 
10074 9219 5-2 North Central 
(Macon) 
2 0.08511 11.7500 
4 Rural Jeff Davis 
County 
12685 13659 9-2 Waycross 2 0.08511 11.7500 
5 Rural Mitchell 
County 
23934 23800 8 -2 Southwest 4 0.17021 5.8750 
6 Rural Franklin 
County 
20287 21748 2 North (Gainesville) 5 0.21277 4.7000 
7 Rural Appling 
County 
17419 18011 9-2 Waycross 6 0.25532 3.9167 
8 Rural Jefferson 
County 
17263 16478 6 East Central (Augusta) 6 0.25532 3.9167 
9 Rural Lumpkin 
County 
20979 27528 2 North (Gainesville) 6 0.25532 3.9167 
10 Rural Toombs 
County 
26067 27959 9-2 Waycross 6 0.25532 3.9167 
11 Rural Wayne County 26565 29407 9-2 Waycross 6 0.25532 3.9167 
12 Rural Sumter County 33200 32084 7 West Central 11 0.46809 2.1364 
13 Urban Spalding 
County 
58417 64708 4 LaGrange 7 0.04110 24.3333 
14 Urban Gordon County 44104 53292 1-1 Rome 10 0.05871 17.0333 
15 Urban Houston 
County 
110765 135715 5-2 North Central 
(Macon) 
11 0.06458 15.4848 
16 Urban Clayton 
County 
236520 275772 3- 3 33 0.19374 5.1616 
17 Urban Fulton County 815827 1033756 3-2 Fulton 113 0.66341 1.5074 
18 Urban Gwinnett 
County 
588450 808167 3 – 4 Gwinnett 118 0.69276 1.4435 
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D  HPV Survey of Physicians 
HPV Survey 
 
The survey is an assessment of HPV vaccination knowledge, barriers, and practice guidelines.  Questions 
are designed to match up with the most current guidelines and recommendations published by the Advisory 
Committee on Immunization Practice (ACIP).  The answers you give will play a part in understanding more 
about the overall health of Georgia citizens. The information will contribute valuable information to 
research.  
 
The survey is private and your participation is voluntary; taking the survey means you consent to take 
part in the study. The answers will not be traced to you, so please give honest answers to each question. 
Thank you. 
 
For the purposes of this survey, we are asking about the quadrivalent HPV vaccine (Gardasil®). 
 
 
 
1. How often do you use the following sources to obtain information about the HPV vaccine? 
 
 
Never Rarely Sometimes Often Always 
Professional 
Organizations (e.g., 
AAFP, ACOG, AAP, 
SGIM)  
 
   ⁪ 
 
  ⁪ 
 
      ⁪ 
 
 
  ⁪  
 
 
  ⁪ 
Advisory Council on 
Immunization Practices 
(ACIP) 
 
  ⁪ 
 
      ⁪ 
 
    ⁪ 
 
     ⁪ 
 
  ⁪ 
State and local 
immunization 
Programs 
  ⁪   ⁪     ⁪  ⁪   ⁪ 
Colleagues 
  ⁪   ⁪     ⁪  ⁪   ⁪ 
Pharmaceutical 
representative   ⁪   ⁪     ⁪  ⁪   ⁪ 
Internet websites 
  ⁪   ⁪     ⁪      ⁪   ⁪ 
Media 
  ⁪   ⁪     ⁪      ⁪   ⁪ 
Medical conferences 
  ⁪   ⁪     ⁪  ⁪   ⁪ 
Grand rounds/local 
institutional lectures   ⁪   ⁪     ⁪  ⁪   ⁪ 
 
 
 
 
 
 
Please go to next section 
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2. Please answer the following true/false questions and base your answers on your current 
understanding of HPV and HPV vaccine, without looking at other sources of information.  Feel free 
to check ”Unsure” when you do not know the answer.  (Please check box that applies for each 
statement. 
 
 True False Unsure 
Most HPV infections resolve without medical intervention. 
   ⁪    ⁪   ⁪ 
HPV is a relatively uncommon sexually transmitted infection. 
   ⁪    ⁪   ⁪ 
HPV causes genital warts in males and females. 
   ⁪    ⁪   ⁪ 
Almost all cervical cancers are caused by HPV infection. 
   ⁪    ⁪   ⁪ 
The FDA approved the quadrivalent HPV vaccine for use in 
females ages 9-26.    ⁪    ⁪   ⁪ 
Females who have been diagnosed with HPV infection should 
not be given the HPV vaccine.    ⁪    ⁪   ⁪ 
The FDA approved the quadrivalent HPV vaccine for use in 
males for permissive use for ages 9-26.    ⁪    ⁪   ⁪ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please go to next section 
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3. How strongly would you agree or disagree that the following are barriers related to immunizing your 
patients against HPV? 
 
 Strongly 
Disagree 
Somewhat 
Disagree 
 
Neutral 
Somewhat 
Agree 
Strongly 
Agree 
My concerns about the 
safety of HPV vaccine   ⁪    ⁪    ⁪    ⁪   ⁪ 
My concerns about the 
efficacy of HPV vaccine   ⁪    ⁪    ⁪    ⁪   ⁪ 
Administering a new 
vaccine with a limited 
track record of safety 
 
  ⁪ 
 
   ⁪ 
 
   ⁪ 
 
   ⁪ 
 
  ⁪ 
Adding another vaccine 
to the vaccine schedule   ⁪    ⁪    ⁪    ⁪   ⁪ 
Lack of information 
about the quadrivalent 
HPV vaccine 
 
  ⁪ 
 
   ⁪ 
 
   ⁪ 
 
   ⁪ 
 
  ⁪ 
The upfront cost of 
purchasing private stock 
HPV vaccine to my 
practice 
 
  ⁪ 
 
   ⁪ 
 
   ⁪ 
 
   ⁪ 
 
  ⁪ 
The cost of stocking HPV 
vaccine   ⁪    ⁪    ⁪    ⁪   ⁪ 
Lack of adequate 
reimbursement for HPV 
vaccination 
 
  ⁪ 
 
   ⁪ 
 
   ⁪ 
 
   ⁪ 
 
  ⁪ 
Failure of some insurance 
companies to cover the 
cost of vaccination 
 
  ⁪ 
 
   ⁪ 
 
   ⁪ 
 
   ⁪ 
 
  ⁪ 
The time it takes to 
discuss HPV vaccination 
with patients and /or 
parents 
 
  ⁪ 
 
 
   ⁪ 
 
   ⁪ 
 
   ⁪ 
 
  ⁪ 
Difficulty ensuring that 
patients will complete the 
3-dose HPV vaccination 
series 
 
  ⁪ 
 
   ⁪ 
 
   ⁪ 
 
   ⁪ 
 
  ⁪ 
HPV vaccination is not 
required for school 
attendance 
  ⁪    ⁪    ⁪    ⁪   ⁪ 
 
 
 
 
 
 
 
 
 
 
 
Please go to next section 
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4. How often have you experienced the following parental barriers to immunizing female patients 
against HPV? 
 
Check here if you don’t recommend HPV vaccine in your clinic practice and skip to 
Question 9    
 
 Never 
0% 
Rarely 
1-25% 
Sometimes 
26-50% 
Often 
51-75% 
Always 
>75% 
Parent concern about 
vaccine Safety ⁪ ⁪ ⁪ ⁪ ⁪ 
Parent concern about 
vaccine efficacy ⁪ ⁪ ⁪ ⁪ ⁪ 
Parent reluctance to 
discuss 
sexuality/sexually 
transmitted infections 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
Parent concern that 
adolescent will assume 
that a parent who agrees 
to HPV vaccination 
condones premarital sex 
 
⁪ 
 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
Parent concern 
vaccinated child will 
practice riskier sexual 
behaviors 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
Lack of parent 
education/understanding 
about HPV infection 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
Parent requests that 
HPV vaccination be 
deferred 
⁪ ⁪ ⁪ ⁪ ⁪ 
Parent believes child is 
not at risk for HPV 
infection 
⁪ ⁪ ⁪ ⁪ ⁪ 
Parent won’t consent to 
vaccination ⁪ ⁪ ⁪ ⁪ ⁪ 
Parent opposition to 
HPV vaccination for 
moral or religious 
reasons 
⁪ ⁪ ⁪ ⁪ ⁪ 
Parent believes child is 
too young for the HPV 
vaccine 
⁪ ⁪ ⁪ ⁪ ⁪ 
Parent concern about 
negative media reports 
related to the HPV 
vaccine 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
 
⁪ 
 
   
 
 
Please go to next section 
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5.  In the past 12 months, how often did you recommend the HPV vaccine to your female           
patients, in the following age groups: 
 
  
 
   Never 
     0% 
 
 
  Rarely 
  1-25% 
 
 
 Sometimes 
    26-50% 
 
 
  Often 
 51-75% 
 
 
 Always 
  >75% 
Do not see 
patients in  
this age  
group 
Ages 9-10 
   ⁪    ⁪     ⁪   ⁪   ⁪     ⁪ 
Ages 11-12 
   ⁪    ⁪     ⁪   ⁪   ⁪     ⁪ 
Ages 13-17 
   ⁪    ⁪     ⁪   ⁪   ⁪     ⁪ 
Ages 18-26 
   ⁪    ⁪     ⁪   ⁪   ⁪     ⁪ 
 
 
 
6. In the past 12 months, how often did you administer at least one does of the HPV vaccine to your female 
patients, in the following age groups: 
 
  
 
   Never 
     0% 
 
 
  Rarely 
  1-25% 
 
 
 Sometimes 
    26-50% 
 
 
  Often 
 51-75% 
 
 
Always 
 >75% 
Do not see  
patients in 
this 
age group 
Ages   9-10  
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   11-12 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   13-17 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   18-26 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please go to next section 
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7. In the past 12 months, how often did your female patients or parents of your female 
patients in the following age groups refuse  HPV vaccination (i.e., did not agree to vaccination 
currently or at a later date)? 
 
 
 
 
 
 
   Never 
     0% 
 
 
  Rarely 
  1-25% 
 
 
 Sometimes 
    26-50% 
 
 
Often 
 51-75% 
 
 
Always 
 >75% 
Do not see  
patients in 
     this 
age group 
Ages   9- 10 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   11- 12 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   13- 17 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   18- 26 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
 
 
8. The ACIP has recommended optional HPV vaccination for boys and young men to protect them from 
genital warts, although the ACIP stopped short of recommending its routine use in boys. How often 
would you recommend vaccination to males in the following age groups: 
 
  
 
   Never 
     0% 
 
 
  Rarely 
  1-25% 
 
 
 Sometimes
    26-50% 
 
 
Often 
 51-75%
 
 
Always
 >75%
Do not see 
patients in
     this 
age group
Ages   9- 10 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   11- 12 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   13- 17 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
Ages   18- 26 
   ⁪    ⁪     ⁪    ⁪    ⁪    ⁪ 
 
 
 
The remaining questions are included so that we will know about the physicians reached by this 
survey and the characteristics of their practices. 
9.  Are you a Vaccine for Children (VFC) provider?      ⁪    Yes      No       Don’t know 
 
 
 
 
 
 
 
Please go to next section 
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10.  Which of the following describes your primary clinical specialty? (choose one) 
⁪ Pediatrics ⁪ Obstetrics/Gynecology 
⁪ Family Medicine ⁪ Other (Specify): _____________________ 
⁪ Internal Medicine ⁪ Academic 
 
 
 
11. Including you, how many physicians are in your practice setting? 
⁪ 1     ⁪ 2-5     ⁪ 6-9     ⁪ 10-14        ⁪ 15 -25      ⁪ 26-49       ⁪ 50+ 
 
 
12. Which of the following best characterizes your practice situation? 
⁪ Single Specialty     ⁪ Multispecialty      ⁪ Other (Specify) 
 
 
 
13. About what percent of your patients use the following primary payment methods? 
(Please approximate; groups may not sum up to 100%) 
 
 
   0%   1-25%  26-50%  51-75% 76-100% 
Private insurance 
 ⁪   ⁪   ⁪   ⁪   ⁪
Medicaid  
 ⁪   ⁪   ⁪   ⁪   ⁪
PeachCare (Georgia’s Children’s Health 
Insurance Program (CHIP)  ⁪   ⁪   ⁪   ⁪   ⁪
Uninsured/self-pay 
 ⁪   ⁪   ⁪   ⁪   ⁪ 
Medicare 
 ⁪   ⁪   ⁪   ⁪   ⁪
Other 
 ⁪   ⁪   ⁪   ⁪   ⁪
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14.  Compared to my clinical peers, I am often among the first to use a newly recommended 
vaccine. 
 
Strongly          Somewhat                                Somewhat         Strongly 
             Disagree          Disagree           Neutral              Agree               Agree 
           ⁪             ⁪            ⁪           ⁪            ⁪  
 
15. I tend to wait to adopt new medications, vaccines, or procedures until I hear about them 
from several trusted colleagues. 
 
Strongly          Somewhat                                Somewhat         Strongly 
             Disagree          Disagree           Neutral              Agree               Agree 
           ⁪             ⁪            ⁪           ⁪            ⁪  
 
 
16. Which of the following best describes the geographic location of your clinical practice? 
⁪ Urban ⁪ Rural 
⁪ Suburban ⁪ Other (Specify): _____________________ 
 
 
     17.   What is your age?      ⁪⁪  years   
 
    
 
      18.    Are you:     ⁪  Male     ⁪ Female 
 
 
19.  Which term best describes your race/ethnic group? 
        ⁪ White/Caucasian ⁪  Black/African-American 
     ⁪  Asian ⁪  American Indian/Alaska Native 
     ⁪  Native Hawaiian/Pacific Islander ⁪  Mixed race 
        ⁪  Other ⁪  Prefer not to answer 
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20.  Are you Hispanic or Latino?         ⁪ Yes          ⁪ No 
  
21.  In what year did you complete residency training?   ⁪⁪⁪⁪ 
 
 
22.   In what zip code is your primary practice located?   ⁪⁪⁪⁪ 
 
 
 23.    Date survey completed:  mm/dd/yyyy   ⁪⁪ / ⁪⁪ / ⁪⁪⁪⁪ 
 
 
Do you have and additional comments or suggestions that apply to the HPV vaccine from your 
perspective that you are willing to share? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is the end of the survey.  Thank you for your time 
 
 
 
 
End of Survey 
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E.  First Email to Physicians 
(First email sent to MD offices informing MD of upcoming survey) 
 
Good Afternoon!  I am a public health nurse and a doctoral candidate at Georgia Southern 
University in the College of Public Health. Your medical practice was selected as part of a 
statistical sample of physician practices in Georgia to take part in a survey pertaining to the 
quadrivalent HPV vaccine, Gardasil® .  
  
I hope you will find the time to complete the survey when it is sent to this office. The entire 
process will take less than 10 minutes. The 23 item survey is to obtain information on Georgia 
physician knowledge, barriers, and ACIP practice as it pertains to the HPV vaccine, Gardasil® . 
The information will add to the current knowledge of immunization practice in Georgia. A 
similar survey was conducted in Texas and Florida. This study has been approved by the Georgia 
Southern University Institutional Review Board.  To decrease the amount of time this takes, only 
one physician (or his/her representative) is requested to complete the survey regardless of how 
many physicians practice at this location. 
  
I will send a second e-mail instructing you how to access the survey online. If there is someone 
else in this office who should receive this e-mail, please let me know by return e-mail and I will 
make the correction.  If you request, I can send the survey by postal mail with a return postage 
paid envelope. As you can see, I am doing what I can to decrease the amount of time you spend 
on the survey. Please know all responses will be held confidential.  For every survey completed, 
$1 will be donated to the American Cancer Society. 
 
Thank you very much for your time, I know it is valuable. 
  
Elizabeth Dixon, RN, BSN  
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F.  Second Email with Internet Link 
Good Day, 
I am a public health nurse and a doctoral student at Georgia Southern University in Statesboro 
Georgia in the college of Public Health. Your medical practice has been selected to take part in a 
survey pertaining to the quadrivalent HPV vaccine, Gardasil® . The survey is confidential and 
has been approved by the Georgia Southern University Institutional Review Board. 
Here is a link to the survey. 
This link is uniquely tied to this survey and your email address. Please do not forward this 
message. Only one physician (or his/her representative or nurse) is requested to complete the 
online survey regardless of how many physicians practice at this location. If a nurse or physician 
representative completes the survey on behalf of the physician, please respond as if you are the 
physician. For example, there is a question “in what year did you complete residency training?” 
Please respond with the answer that represents the year the physician completed his/her 
residency, rather than the year you completed your training. 
I hope you will find the time to complete the enclosed survey. The entire process will take less 
than 10 minutes. The 23 item survey is to obtain information on Georgia physician knowledge, 
barriers, and ACIP practice as it pertains to the HPV vaccine, Gardasil® . The information will 
add to the current knowledge of immunization practice in Georgia. A similar survey was 
conducted in Texas and Florida. 
Thank you very much for your time. If you have any questions or concerns, I may be reached by 
phone at 912-898-1222 or by email at ed00027@georgiasouthern.edu. Please know all responses 
will be held confidential. For every survey completed, $1 will be donated to the American 
Cancer Society. 
Sincerely, 
Elizabeth T. Dixon, RN, BSN 
 
 
Please note: If you do not wish to receive further emails from us, please click here, and you will 
be automatically removed from our mailing list. 
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G.  Postal Mail Survey  
(For those who did not have email address or who had not responded to email survey) 
Good Morning,   
 
I am a public health nurse and a doctoral student at Georgia Southern University in 
Statesboro Georgia.  Your medical practice has been selected to take part in a survey 
pertaining to the quadrivalent HPV vaccine, Gardasil® . The survey is confidential and has 
been approved by the Georgia Southern University Institutional Review Board.   
 
Only one physician (or his/her representative) is requested to complete the enclosed survey 
regardless of how many physicians practice at this location. If a nurse or physician 
representative completes the survey on behalf of the physician, please respond as if you are 
the physician.  For example, there is a question “in what year did you complete residency 
training?”  Please respond with the answer that represents the year the physician 
completed his/her residency, rather than the year you completed your training.   
  
I hope you will find the time to complete the enclosed survey. The entire process will take 
less than 10 minutes. The 23 item survey is to obtain information on Georgia physician 
knowledge, barriers, and ACIP practice as it pertains to the HPV vaccine, Gardasil® . The 
information will add to the current knowledge of immunization practice in Georgia. A 
similar survey was conducted in Texas and Florida.  
  
Thank you very much for your time.  If you have any questions or concerns, I may be 
reached by phone at 912-898-1222 or by email at ed00027@georgiasouthern.edu. Please 
know all responses will be held confidential.  For every survey completed, $1 will be 
donated to the American Cancer Society. 
 
Sincerely, 
 
Elizabeth T. Dixon, RN, BSN  
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H.  Follow Up Phone Call  
(left on voice mail or with physician answering service) 
 
Hello, [KEY INFORMANT NAME]!  
 
My name is Elizabeth Dixon I am doing my dissertation research at Georgia 
Southern University on the quadrivalent HPV vaccine - Gardasil.   
 
I am calling because this Medical Practice was selected from a random sample of 
all Georgia practices that provide immunizations to their patients. 
 
Your help is needed as a participant in this study. By now this office should have 
received a (MAIL OR EMAIL) survey.  The survey is an assessment of HPV 
vaccination knowledge, barriers, and practice guidelines.   
 
Questions on this survey have been used in Texas, Florida and other states and are 
designed to match up with the most current guidelines and recommendations 
published by the Advisory Committee of Immunization Practice.    
 
The 23-item survey should take no more than 10 minutes to complete. All 
responses will be held confidential; for your information, this study has been 
approved by the IRB at GSU and will contribute valuable information to research 
on immunization practice in Georgia. 
 
Your participation is very much appreciated and I hope you will take the time to 
complete the survey. 
 
If you have not received the survey or would like to have it resent to your office, 
please call 912-898-1222 or you may request by email at 
ed00027@georgisouthern.edu. 
 
Thank you.   
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I.  Follow up Phone Call (during office hours) 
 
Hello, [KEY INFORMANT NAME]!  
 
My name is Elizabeth Dixon I am doing my dissertation research at Georgia 
Southern University on the quadrivalent HPV vaccine - Gardasil.   
 
I am calling you again because your Medical Practice was selected from a random 
sample of all Georgia practices that provide immunizations to their patients. 
 
Your help is needed as a participant in this study. By now your office has received 
two or three (MAIL OR EMAIL) surveys.  The survey is an assessment of HPV 
vaccination knowledge, barriers, and practice guidelines.   
 
The 23-item survey should take no more than 10 minutes to complete. All 
responses are confidential. This study has been approved by the IRB at GSU and 
will contribute valuable information to research on immunization practice in 
Georgia. 
 
Do you have the time now, or should I call back?  When is a good time for me to 
call back? 
 
 
(survey by phone) If you have a few minutes, we can do the survey now! 
 
That’s it.  Your participation is very much appreciated!  Thank you again for the 
time you took away from your practice and with me to answer these questions.  
 
 
 
